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INTRODUCTION
1INTRODUCTION
Cytopenia is a reduction in the number in any of the three types of
peripheral blood cell. A reduction in all the three types of cellular
components is termed pancytopenia and this involves anemia, leucopenia,
and thrombocytopenia.
Initially, mild impairment in marrow function may go undetected
and pancytopenia may become apparent only during times of stress or
increased demand (e.g., bleeding or infection). As severity increases, the
peripheral blood count decreases even in the steady state. Peripheral
pancytopenia may be a manifestation of wide variety of diseases which
can primarily or secondarily affect the bone marrow.
The frequency of underlying pathology causing pancytopenia
varies considerably depending upon various factors including geographic
distribution and genetic disturbances. The severity of pancytopenia and
the underlying pathology determine the management and prognosis of the
patients with pancytopenia. The basic investigations in a suspected case
of pancytopenia include Complete Blood Count with peripheral blood
film and Reticulocyte count.
2The  presenting  symptoms  are  usually  attributable  to  anemia  or
thrombocytopenia. Red blood corpuscles survive much longer than
platelets or neutrophils.Hence  anaemia develops slowly (unless there is
significant bleeding) and the typical symptoms of tiredness, fatigue,
puffiness of face, edema, lassitude, and effort intolerance may not be
striking in the initial phase.
The platelet count is first to be affected. Mucocutaneous bleeding
is typical of thrombocytopenia with petechial haemorrhages in skin and
mucous membranes (commonest being epistaxis, haematuria, GI
bleeding, menorrhagia, and only rarely intracranial bleeding). The
presence of spontaneous bleeding with platelet count <20 x 109/l indicates
severe marrow failure.
Leucopenia is an uncommon cause of initial presentation, but can
cause a more serious threat to the life in its subsequent course. Infections
usually occur with commensal organisms of the skin or gastrointestinal
tract. Early manifestation of neutropenia is often a sore throat or chest or
soft tissue infection which typically show incomplete response to
antibiotics. Unfortunately, patients with pancytopenia may develop
overwhelming septicemia without any focal sign of infection; the only
clinical features being malaise and fever.
3Pancytopenia can be due to decrease in hematopoietic cell
production in the bone marrow e.g. by infections, toxins, malignant cell
infiltration or suppression or can have normocellular or even
hypercellular marrow, without any abnormal cells, e.g. ineffective
hematopoiesis and dysplasia, maturation arrest of all cell lines and
peripheral  sequestration  of  blood  cells.  Bone  marrow  biopsy  plays  a
significant role in understanding the etiology of pancytopenia. Hence
Bone marrow examination is indicated in all cases of pancytopenia.
Pancytopenia is an important clinico haematological entity
encountered in our day-to- day clinical practice. There are varying trends
in its pattern, treatment modalities, and outcome. There are very few data
about the clinical presentation, and the etiology of pancytopenia in Indian
patients.  The aim of this  study  to evaluate the clinical  presentation and
etiological spectrum of pancytopenia on the basis of peripheral smear and
bone marrow examination.
Hence this study is designed to evaluate the presenting features and
the causes of patients with pancytopenia.
AIMS
&
OBJECTIVES
4                         AIMS AND OBJECTIVES
To evaluate the clinical and etiological profile of patients
presenting with pancytopenia.
REVIEW
OF
LITERATURE
5REVIEW OF LITERATURE
Pancytopenia is defined as a decrease in all cellular elements of the
circulating  blood, including erythrocytes, leukocytes, and platelets. The
degree of decrease in any one of these elements may vary at any time in
the course of the illness. Some disorders that cause pancytopenia may
initially come to attention as single-cell cytopenia. Anemia is defined as
hemoglobin level less than 13g/dl in men and 12g/dl in women.
Thrombocytopenia is a platelet count less than 150,000 per microliter
 and leucopenia is a white blood cell count less than 4,000 per microliter.
Although leucopenia may be caused by lymphopenia or neutropenia, the
most common finding is neutropenia with an absolute neutrophil count
less than 1,500 per microliter.
PRESENTATION
Mild pancytopenia may be asymptomatic, the patient manifesting
findings associated with the primary underlying disorder. Patients with
severe pancytopenia come to medical attention in an explosive, life-
threatening clinical scenario.
6Patients with granulocyte counts less than 500 per microliter may
have overwhelming sepsis. A patient with a platelet count less than
20,000 per microliter may have life-threatening, spontaneous
hemorrhage. Acquired or congenital qualitative platelet dysfunction may
cause increased hemorrhage. Patients may have simultaneous severe
bleeding and infection. Symptoms associated with anemia often are more
insidious because of the usual gradual onset of anemia. In addition to the
findings of the underlying disease, findings at physical examination often
are pallor, fever, necrotic abscess, and spontaneous petechiae and
ecchymoses.
Severe pancytopenia is a medical emergency. Because this
condition is life threatening, immediate supportive care, rapid diagnosis,
and definitive and preventive treatment should be instituted.
Pancytopenia is a symptom complex of an underlying disorder in which
there is an absolute or relative decrease in effective hematopoietic
production of peripheral blood cell elements.
PATHOPHYSIOLOGY
In general, pancytopenia results from one of four pathophysiologic
processes. Absence of hematopoietic progenitors that cause aplastic
anemia is thought to be synonymous with pancytopenia. However,
7pancytopenia may be caused by other pathologic states. A decrease in
normal hematopoiesis may be caused by replacement of the bone marrow
cavity, the site of adult hematopoiesis, through a pathologic process that
may be hematopoietic in origin or be caused by invasion by
extrahematopoietic cells. Reactive myelofibrosis may be present. This
process is called myelophthisis. Ineffective hematopoiesis results in
progenitors that produce normal to increased numbers of cellular
elements that are incapable of normal maturation and succumb to
intramedullary destruction. This situation is manifested in severe folate or
vitamin B12 deficiency or myelodysplasia. Pancytopenia may be caused
by increased peripheral destruction of cellular elements with a
hypercellular marrow incapable of adequate compensatory production.
Some disorders, such as HIV infection, that cause pancytopenia may do
so by more than one mechanism.
DIFFERENTIAL DIAGNOSIS OF PANCYTOPENIA
Pancytopenia with Hypocellular Bone Marrow
Acquired aplastic anemia
Constitutional aplastic anemia (Fanconi’s anemia, dyskeratosis
congenita)
8Some of the myelodysplasias
Rare aleukemic leukemia (AML)
Some cases of acute lymphoid leukemia
Some cases of lymphomas of bone marrow
Pancytopenia with Cellular Bone Marrow
Primary bone marrow diseases/disorders
Myelodysplasia
Paroxysmal nocturnal hemoglobinuria
Myelofibrosis
Some aleukemic leukemia
Myelophthisis
Bone marrow lymphoma
Hairy cell leukemia
Secondary to systemic diseases
9Systemic lupus erythematosus
Hypersplenism
Vitamin B12, folate deficiency
Overwhelming infection
Alcohol
Brucellosis
Sarcoidosis
Tuberculosis
Leishmaniasis
Hypocellular Bone Marrow +/- Cytopenia
Q fever
Legionnaires’ disease
Anorexia nervosa, starvation
Mycobacteria
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HISTORY AND PHYSICAL EXAMINATION
The history and physical examination often lead to the diagnosis of
pancytopenia. Because of the diversity of manifestations and causes of
pancytopenia, a detailed and careful history and physical examination are
required. Anemia may cause increasing fatigue and dyspnea on exertion,
but because of the gradual onset of symptoms, it may be insidious and not
detected earlier. Among elderly patients, increasing signs and symptoms
of congestive heart failure may be evident. Despite severe anemia, the
blood volume may be increased. Leukopenia and neutropenia may cause
unexplained high fevers, shaking chills, and repeated, persistent
infections. Thrombocytopenia may come to attention as increasing
ecchymoses and petechiae, particularly in the lower extremities. Patients
with severe thrombocytopenia may report bleeding from their gums or
oral mucosa or visual changes caused by retinal hemorrhage. Patients
may have signs and symptoms of life-threatening intracranial
hemorrhage. Women of childbearing age may have severe menorrhagia.
The history often determines the duration of pancytopenia. Some
patients notice the gradual onset of increasingly severe symptoms, but for
others, the onset is sudden and fulminant. The history may show the
cause of the pancytopenia. The history of illnesses, medications, and
11
surgical procedures is important. That a patient has undergone
gastrectomy or ileal resection suggests the possibility of vitamin B12
deficiency. A careful drug history, including the months before the onset
of symptoms, is important in ascertaining whether the patient has drug-
induced aplastic anemia. Administration of chemotherapy or high-dose
radiation therapy to the bone marrow often causes expected pancytopenia
of finite duration. A history of collagen vascular disease or rheumatoid
arthritis suggests aplastic anemia or a lymphoproliferative disorder. The
patient should be asked specifically about the presence of dark urine at
the initial morning void, which suggests the presence of paroxysmal
nocturnal hemoglobinuria.
A history of a malignant disease metastatic to bone marrow
suggests the possibility of a myelophthisic process. The primary
malignant tumor may be remote in time; recurrence comes to attention as
bone marrow involvement or a more generalized process accompanied by
constitutional symptoms such as weight loss and night sweats, although
fever also may be symptomatic of infection due to neutropenia.
Secondary hematopoietic malignant diseases or myelodysplastic
syndromes may be caused by earlier chemoradiation therapy.
12
The history should include an adequate dietary evaluation that
includes alcohol ingestion. The possibility of HIV infection should be
entertained, and the history should include potential risk factors. To
determine the possibility of a genetic disorder such as lipid storage
disease or congenital aplastic anemia, a complete family history should
be obtained. Although primarily diagnosed in childhood, these disorders
may occur in young adulthood or later. A travel history should be
established, because infectious diseases may cause pancytopenia.
The physical examination is important in determining the severity
and consequences of pancytopenia and possibly in establishing the
underlying diagnosis. In mild pancytopenia, only pallor may be observed.
With serious thrombocytopenia, ecchymosis and petechiae may be
noticed, particularly on the lower extremities and pressure points. In cases
of severe thrombocytopenia, petechiae and bleeding also may be seen in
the oral mucosa and retina. The latter findings indicate an emergency.
High spiking fevers may indicate the presence of potentially life-
threatening infection. Careful examination for the source of the infection
must be undertaken. In the absence of neutrophils, an infected site
contains necrotic ulcers. Important cutaneous microemboli and rashes
may be present. Sinuses should be percussed for tenderness. A careful,
noninvasive examination of the per rectal area should be performed. In
13
the absence of adequate neutrophils, the findings of pneumonia may be
subtle.
The physical examination should be an attempt to determine the
cause of the pancytopenia. In many disorders, there may be no further
physical findings. However, splenomegaly may indicate that
pancytopenia has been caused by hypersplenism or a myelophthisic state
with extramedullary splenic hematopoiesis. With massive splenomegaly,
the spleen extends into the lower abdomen, and the examination should
begin in the lower abdomen and carefully proceed cephalad. Massive
splenomegaly occurs in Gaucher’s disease, myelofibrosis, hairy cell
leukemia, and lymphoma. Splenomegaly usually does not occur with
aplastic anemia, acute lymphocytic leukemia, ineffective hematopoiesis,
and myelodysplastic syndromes.
Lymphadenopathy may indicate the presence of lymphoma, acute
or chronic lymphocytic leukemia, or metastatic carcinoma. Examination
of the breasts should be performed, because pancytopenia may
accompany metastatic breast carcinoma. Skin and joint findings
suggesting collagen vascular disease or arthritis may indicate the
presence of immunologically mediated pancytopenia.
14
LABORATORY STUDIES AND DIAGNOSTIC TESTS
Laboratory studies are the most definitive aspect of the evaluation
for pancytopenia. An immediate and careful examination of a good-
quality peripheral blood smear is mandatory. The complete blood cell
count and differential count may indicate that some cell lines are more
severely affected than others. Cell lines should be individually examined.
Erythroid macrocytosis may indicate ineffective hematopoiesis, as
in vitamin B12 or folate deficiency, or the defect may occur as
leukoerythroblastosis in myelophthisic disorders. The latter condition
may be associated with poikilocytosis, nucleated RBCs, and teardrop-
shaped cells. Nucleated RBCs are findings of stress erythropoiesis.
Although aplastic anemia is classified as normochromic normocytic
anemia, macrocytosis indicative of terminal stress erythropoiesis may be
present. Polychromatophilia is indicative of erythroid production.
Rouleaux formation may indicate lymphoma or multiple myeloma.
Blasts may indicate an underlying leukemia or myelodysplastic
syndrome. Hairy cell leukemia, chronic lymphocytic leukemia, and non-
Hodgkin’s lymphoma may be associated with the finding of circulating
malignant cells the presence of which is enough  to confirm a diagnosis.
In some bone marrow failure syndromes, such as aplastic anemia, an
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absence of myeloid cells causes relative lymphocytosis. A
leukoerythroblastic smear has a few immature myeloid cells in addition to
the RBC changes. Pelger–Huet anomaly and hypogranulation of the
myeloid cells suggest an underlying myelodysplastic syndrome.
Hypersegmentation of polymorphonuclear leukocytes is associated with
megaloblastic anemia. An almost normal differential count and
percentage of myeloid cells may indicate peripheral destruction caused by
hypersplenism. Decreased numbers of small platelets indicate decreased
platelet production, and the presence of giant platelets is associated with a
myelophthisic process or compensatory thrombopoiesis.
Most important, examination of the peripheral blood must include
a reticulocyte count with a supravital stain for numeric assessment of
erythroid production. For more accurate measurement of erythropoiesis,
the reticulocyte count should be corrected for an abnormal hemoglobin
level.
In all cases of pancytopenia, bone marrow aspiration and biopsy
should be performed immediately after the peripheral blood examination.
In conjunction with the peripheral blood findings, these studies can help
identify the cause of the pancytopenia in most cases. Aspirate
examination of individual cell lines and cells allows the diagnosis of
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malignant disease of the hematopoietic system, lipid storage disorders,
megaloblastic anemias, and myelodysplastic syndromes. Metastatic
cancer cells sometimes are found in the aspirate, although these findings
are more frequent in core biopsy. Prussian blue stains may demonstrate
the presence of the ringed sideroblasts indicative of the myelodysplastic
syndromes. Examination of the aspirate should include flow cytometry,
which may aid in the identification of clonal abnormal cell populations.
Cytogenetic abnormalities are found in the congenital bone marrow
failure syndromes, such as Fanconi’s aplastic anemia, and in some types
of leukemia and myelodysplastic syndrome.
Extremely important in the evaluation of pancytopenia is core bone
marrow biopsy, especially if a hypocellular aspirate is obtained. The
biopsy provides the only true estimate of bone marrow cellularity.
Although hypocellular marrow usually is associated with aplastic anemia,
the possibility of a hypocellular myelodysplastic syndrome must be
considered, and the core biopsy should be carefully correlated with the
aspirate biopsy and cytogenetic studies. Bone marrow biopsy allows the
diagnosis of myelofibrosis and increases the yield of diagnosis of
metastatic carcinoma, mycobacterial infection, lymphoma, and hairy cell
leukemia. No specific marrow findings are associated with HIV infection,
although some of the secondary consequences such as granuloma or
17
lymphoma may be demonstrated in the marrow. Bone marrow aspiration
and biopsy often establish the diagnosis among patients with an enlarged
spleen, particularly if the splenomegaly is caused by an infiltrative
disorder or extramedullary hematopoiesis.
Careful evaluation of the peripheral blood and bone marrow often
establish the cause of the pancytopenia. The need for further laboratory
testing is dictated by the results of these examinations.Below are
discussed some of the common causes of pancytopenia.
MEGALOBLASTIC ANEMIA
Megaloblastic anemia most commonly results from folate or
cobalamin (vitamin B12 ) deficiency. Folate deficiency usually is
nutritional in origin. It may be seen in alcoholics and the elderly poor but
also is seen in patients on hyperalimentation or hemodialysis. Diagnosis
is based on measurements of folate in serum, which furnishes information
about the current level of folate, and in red cells, which provides data on
folate levels over the preceding 6 weeks. Nutritional folate deficiency is
treated with folic acid. Folate deficiency as a result of malabsorption
occurs in tropical and nontropical sprue.
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The most common cause of cobalamin deficiency is pernicious anemia
(PA), a condition in which the portion of gastric mucosa that contains the
parietal cells is destroyed through an autoimmune mechanism. Cobalamin
deficiency leads not only to megaloblastic anemia but also to a
demyelinating disease that manifests itself as peripheral neuropathy,
spastic paralysis with ataxia (so-called combined system disease of the
spinal cord), dementia, psychosis, or a combination of the foregoing.
"Subtle" cobalamin deficiency, manifested as neurologic symptoms
without anemia, appears to be relatively widespread among the elderly.
Definition:
Megaloblastic anemia are disorders caused by impaired DNA
synthesis. The presence of megaloblastic cells is the morphologic
hallmark of this group of  anemias. Megaloblastic red cell precursors are
larger than normal and have more cytoplasm relative to the size of the
nucleus.  Promegaloblasts  show  a  blue  granule-free  cytoplasm  and  a
granular chromatin that contrasts with the ground-glass texture of its
normal counterpart. As the cell differentiates, the chromatin condenses
more slowly than normal into dark aggregates that coalesce, giving the
nucleus a characteristic fenestrated appearance. Condensation of
chromatin to a homogeneous mass either fails or is delayed. The growing
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maturity of the cytoplasm as it acquires hemoglobin contrasts with the
immature-looking nucleus, a feature termed nuclear-cytoplasmic
asynchrony. Megaloblastic granulocyte precursors are larger than normal.
They show nuclear-cytoplasmic asynchrony, with cytoplasm that looks
less mature than the cytoplasm of their normal counterparts. A
characteristic cell is the giant metamyelocyte, which has a large
horseshoe-shaped nucleus, sometimes irregularly shaped, containing
ragged chromatin. Megaloblastic megakaryocytes may be abnormally
large, with deficient granulation of the cytoplasm. In severe
megaloblastosis, the nuclteus may show unattached lobes.
By far the most common causes of megaloblastic anemia are folate
deficiency and cobalamin deficiency.
20
 Causes of Megaloblastic Anemias
Folate deficiency
Decreased intake
 Poor nutrition
 Old age, poverty,
alcoholism
 Hyperalimentation
 Hemodialysis
 Premature infants
 Spinal cord injury
 Children on synthetic
diets
 Goat's milk anemia
Impaired absorption
 Nontropical sprue
 Tropical sprue
 Other disease of the
small intestine
Increased requirements
 Pregnancy
 Increased cell turnover
 Chronic hemolytic
anemia
Acute megaloblastic anemia
 Nitrous oxide exposure
 Severe illness with
 Extensive transfusion
 Dialysis
 Total parenteral nutrition
 Exposure to weak folate antagonists (e.g.,
trimethoprim or low-dose methotrexate)
Drugs
 Dihydrofolate reductase inhibitors
 Antimetabolites
 Inhibitors of deoxynucleotide synthesis
 Anticonvulsants
 Oral contraceptives
 Others
Inborn errors
 Cobalamin deficiency
 Imerslund-Gräsbeck disease
 Congenital deficiency of intrinsic factor
 Transcobalamin II deficiency
 Errors of folate metabolism
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 Exfoliative dermatitis
 Cobalamin deficiency
Impaired absorption
 Gastric causes
 Pernicious anemia
 Gastrectomy
 Zollinger-Ellison
syndrome
 Intestinal causes
 Ileal resection or disease
 Blind loop syndrome
 Fish tapeworm
 Pancreatic insufficiency
Decreased intake
 Vegeterians
 Congenital folate malabsorption
 Dihydrofolate reductase deficiency
N5-methyl FH4 homocysteine–
methyltransferase deficiency
 Errors of cobalamin metabolism
 "Cobalamin mutant" syndromes with
homocystinuria
Other errors
  Hereditary orotic aciduria
  Lesch-Nyhan syndrome
  Thiamine-responsive megaloblastic anemia
 Unexplained
  Congenital dyserythropoietic anemia
  Refractory megaloblastic anemia
  Erythroleukemia
Laboratory Features:
Peripheral smear:
All cell lines are affected. Erythrocytes vary markedly in size and
shape, often are large and oval, and in severe cases can show basophilic
stippling and nuclear remnants (Cabot rings, and Howell-Jolly bodies).
Erythroid activity in the marrow is enhanced, although the megaloblastic
cells usually die before they are released, accounting for the reduced
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reticulocyte count. The more severe the anemia, the more pronounced the
morphologic changes in the red cells. When the hematocrit is less than 20
percent, erythroblasts with megaloblastic nuclei, including an occasional
promegaloblast, may appear in the blood. The anemia is macrocytic
(mean corpuscular volume [MCV] = 100–150 fl or more), although
coexisting iron deficiency, thalassemia trait, or inflammation can prevent
macrocytosis. Slight macrocytosis often is the earliest sign of
megaloblastic anemia.
Neutrophil nuclei often have more than the usual three to five
lobes. Typically, more than 5 percent of the neutrophils have five lobes.
Cells may contain six or more lobes, a morphology never seen in normal
neutrophils. In nutritional megaloblastic anemias hypersegmented
neutrophils are an early sign of megaloblastosis and persist in the blood
for many days after treatment.Even presence of a single hypersegmented
neutrophil should warrant evaluation for megaloblastic anemia.
Chromosomes are elongated and broken. Specific therapy corrects these
abnormalities, usually within 2 days, although some abnormalities do not
disappear for months. Platelets are slightly smaller than normal and vary
more widely in size (increased platelet distribution width).
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Bone Marrow in  megaloblastic anemia:
Aspirated marrow is cellular and shows striking megaloblastic
changes, especially in the erythroid series. The high apoptosis rate of
erythroid precursor cells in the marrow creates more globin lysis and,
thus, jaundice. Sideroblasts are increased in number and contain
increased numbers of iron granules. The ratio of myeloid to erythroid
precursors falls to 1:1 or lower, and granulocyte reserves may be
decreased. In severe cases, promegaloblasts containing an unusually large
number of mitotic figures are plentiful.
Treatment  consists of  parenteral cyanocobalamin (vitamin B12 )
or oral vitamin B12 to  replace  daily losses and  refill storage
pools.Toxicity is unusual, although severe hypokalemia leading to cardiac
arrhythmias can be seen.A typical treatment schedule consists of 1000
micrograms of cobalamin IM daily for 2 weeks, then weekly until the
hematocrit is normal, and then monthly for life. For neurologic
manifestations, 1000 micrograms every 2 weeks for 6 months is
recommended. Higher doses are given for certain inherited disorders
(e.g., TCII deficiency). Cobalamin should be given by mouth to patients
with dietary cobalamin deficiency and patients (e.g., hemophiliacs) who
cannot take IM injections.
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Transfusion occasionally is required when the hematocrit is less
than 15 percent or the patient is debilitated, infected, or in heart failure. In
such instances, packed cells should be given slowly to avoid pulmonary
edema. Infections can impair the response to cobalamin and must be
treated vigorously.
HYPERSPLENISM
The spleen culls aged and abnormal cells from the blood; removes
intraerythrocytic inclusions through a process called pitting; sequesters
approximately one third of the normal intravascular platelet pool;
removes bacteria, foreign particles, and tumor cells from the blood; and
by virtue of the T and B lymphocytes and macrophages in the white pulp
plays a role in immune surveillance and antibody formation.
Exaggeration or impairment of some or all of these splenic functions
results in hypersplenism or hyposplenism, respectively. Hypersplenism
can be caused by splenic enlargement as a result of vascular engorgement
or cellular infiltration. Splenomegaly resulting from vascular
engorgement, such as portosplenal vein hypertension, or from infiltrative
disease commonly leads to a combination of neutropenia,
thrombocytopenia, and anemia. Hypersplenism also can be caused by
moderate or minimal splenic enlargement as a result of exaggerated
removal of physically abnormal (e.g., hereditary spherocytosis) or
antibody-coated blood cells (e.g., immune thrombocytopenia).
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Definition:
The designation hypersplenism refers to exaggeration of the
spleen's normal filtration and phagocytic functions. The disorder can
occur primarily by enlargement of the spleen from vascular congestion,
histiophagocytic hyperplasia, cellular infiltration, or secondarily by the
inability of physically abnormal red cells, such as sickle cells, or
antibody-coated cells, such as in immune thrombocytopenia purpura, to
navigate the circulation or avoid engulfment by the mononuclear
phagocyte population of the normal spleen. Hypersplenism usually is
associated with the triad of splenomegaly, blood cytopenias, and
compensatory marrow hyperplasia; it is characteristically corrected by
splenectomy.
Pathophysiology:
Splenomegaly increases the proportion of blood channeled through
the red pulp, causing inappropriate hypersplenic sequestration of normal
and abnormal blood cells.Spleen enlargement may result from expansion
of the red pulp compartment in any red cell sequestration process;
extramedullary hematopoiesis, notably in idiopathic myelofibrosis;
hyperplasia or neoplasia involving the white pulp, such as infectious
mononucleosis or lymphoma, respectively; or histiophagocytic
hyperplasia.
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The increased size of the filtering bed is more pronounced when
the splenomegaly is caused by congestion (as in portal hypertension) than
when it is caused by cellular infiltration (as in leukemias, thalassemias, or
amyloidosis). Nevertheless, even in space-occupying disorders such as
Gaucher disease and myelofibrosis, splenomegaly may be associated with
severe hypersplenic sequestration of normal cells.
Splenomegaly increases the vascular surface area and thereby the
marginated neutrophil pool. Platelets are especially likely to be
sequestered in an enlarged spleen, and up to 90 percent of the total
number of platelets in blood may be found in massively enlarged spleens.
However, sequestered white cells and platelets survive in the spleen and
may be available when increased demand requires neutrophils or
platelets, although their release may be slow.
Red cells, on the other hand, often are destroyed prematurely in the
red pulp. Anemia in patients with splenomegaly has been considered the
result of dilution of red cells in an expanded plasma volume. However,
expansion, as measured by radiolabeled albumin or fibrinogen, results
more from an increase in the splenic pool of protein rather an increase in
circulating plasma volume.
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Varying amounts of erythrophagocytosis are present, reflecting the
normal culling of senescent red cells. Erythrophagocytosis increases as a
result of hemolytic anemia and viral infections, and in alloimmunized
transfusion recipients. Macrophages within the sinusoids contain red cell
fragments. When the process is pronounced, the littoral cells become
cuboidal and stand out on the basement membrane ("hobnails"). Sickle
cell disease and red cell membrane disorders such as hereditary
spherocytosis lead to sequestration of the poorly deformed red cells in the
cords but little extrasinusoidal erythrophagocytosis, in contrast to
immune hemolytic anemia where macrophage erythrophagocytosis is
prominent.
Splenomegaly with Appropriate
Hypersplenism
Hereditary hemolytic anemias
Splenomegaly with
Inappropriate Hypersplenism
Congestion (Banti syndrome)
Hereditary spherocytosis Cirrhosis of the liver
Hereditary elliptocytosis Portal vein thrombosis
Thalassemia Splenic vein obstruction
Sickle cell anemia (infants) Budd-Chiari syndrome
Congestive heart failure
Autoimmune cytopenias
Idiopathic thrombocytopenia Infiltrative disease
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Essential neutropenia Leukemias, chronic and acute
Acquired hemolytic anemia Lymphomas
Polycythemia vera
Infections and inflammations Agnogenic myeloid metaplasia
Infectious mononucleosis Gaucher disease
Subacute bacterial endocarditis Niemann-Pick disease
Miliary tuberculosis Glycogen storage disease
Rheumatoid arthritis (Felty
syndrome)
Amyloidosis
Lupus erythematosus, Sarcoidosis
Brucellosis, Leishmaniasis
Schistosomiasis,Malaria
Laboratory Features:
The characteristic triad of hypersplenism is (1) splenomegaly, (2)
blood cytopenias, and (3) hyperplasia of the corresponding lineage in the
marrow. The blood cell morphology usually is normal, although a few
spherocytes may result from metabolic conditioning of red cells during
repeated slow transits through the expanded red pulp. A compensatory
increase in red cell production usually is evident by an increased
reticulocyte count. This finding may be quantitatively less evident
because the spleen preferentially sequesters reticulocytes. The presence
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of a compensatory increase in neutrophil or platelet production is more
difficult to identify morphologically. Tests such as epinephrine
mobilization have been used to distinguish sequestration from ineffective
cellular production. Epinephrine releases neutrophils and platelets from
the spleen, but the test may be difficult to interpret since epinephrine also
releases the cells from marginal pools. The pathophysiology usually can
be inferred from the associated clinical findings and other tests including
the marrow examination.
Pancytopenia is a common finding in patients with hepatic
cirrhosis and portal hypertension. However, why some patients with
cirrhosis develop marked cytopenias and others do not is not clear. About
one third of patients with cirrhosis develop severe hypersplenism.
Decompensated liver disease and history of alcohol consumption are
independent risk factors for hypersplenism. The presence of
hypersplenism in patients with chronic liver disease increases the
probability of variceal bleeding.
MYELOPHTHISIC ANEMIA
Myelophistic anemia refers to anemia resulting from the presence
of spotty to massive marrow infiltration with abnormal cells or tissue
components. the term myelophthisic anemia is best reserved for marrow
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replacement by nonhematologic tumors and nonhematopoietic tissue. The
two major features of idiopathic myelofibrosis are extramedullary
hematopoiesis (in spleen, liver, and other organs) and bone marrow
fibrosis. Minimal to moderate involvement usually does not cause
symptoms or hematologic changes. However, such infiltration is
clinically significant because in patients with an established diagnosis of
cancer, it indicates metastatic dissemination of the tumor and usually an
incurable disorder. Extensive infiltration may lead to pancytopenia. The
condition accompanied by teardrop-shaped red cells, prematurely
released nucleated red cells, and immature myeloid cells is referred to as
leukoerythroblastic reaction. In myelofibrotic disorders of both idiopathic
and secondary origin, the malignant clone releases fibroblastic growth
factors. The resultant fibrosis restricts the available bone marrow space
and disrupts bone marrow architecture. The disruption may cause
cytopenias with production of deformed red cells, especially poikilocytes
and teardrop-shaped cells, and premature release of erythroblasts,
myelocytes, and giant platelets.
The anemia usually is mild to moderate, but it can be severe. White
cell and platelet counts may vary, but the most characteristic feature is the
morphologic appearance of red cells on the blood film. These cells may
show anisocytosis and poikilocytosis, but the presence of teardrop forms
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and nucleated red cells is particularly suggestive of marrow infiltration.
The combination of nucleated red cells and immature myeloid precursors
constitutes the leukoerythroblastic picture that is characteristic of marrow
infiltration. Marrow biopsy is the most reliable procedure used to
diagnose marrow-infiltrative disease and should be performed in all
patients with suspected metastatic carcinoma or hematologic features of
myelophthisic anemia. The inability to aspirate marrow (dry tap) leads to
a high degree of suspicion of marrow replacement.
APLASTIC ANEMIA
Aplastic  anemia  is  defined  as  the  failure  of  bone  marrow  to
produce blood cell components. The hallmarks of the disease are
pancytopenia and a hypocellular bone marrow. Aplastic anemia is a rare
disease. Inherited forms of the disorder are rare and consist of Fanconi’s
anemia, dyskeratosis congenita, and Schwachman syndrome. Among
patients with the acquired disorder, idiopathic aplastic anemia, in which
no cause is apparent, accounts for approximately 65% of all cases of
aplastic anemia
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Acquired aplastic anemia
Idiopathic
Secondary
Chemicals
Benzene
Insecticides
Glue
Solvents
Drugs
Cytotoxic agents
Antibiotics
Nonsteroidal anti-inflammatory drugs
Anticonvulsive agents
Gold salts
Radiation
Viruses
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Epstein-Barr virus
Non-A, non-B, non-C hepatitis viral agent
Human immunodeficiency virus
Immune and rheumatologic diseases
Graft-versus-host disease
Rheumatoid arthritis
Systemic lupus erythematosus
Paroxysmal nocturnal hemoglobinuria
Pregnancy
Inherited aplastic anemia
Fanconi’s anemia
Dyskeratosis congenita
Schwachman syndrome.
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Pathophysiology:
The pancytopenia in aplastic anemia reflects failure of the
hematopoietic process manifested as a severe decrease in the numbers of
all hematopoietic progenitor cells. Two mechanisms have been suggested
for bone marrow failure. The first mechanism is direct hematopoietic
injury  by  chemicals  (eg,  benzene),  drugs,  or  radiation  to  both
proliferating and quiescent hematopoietic cells. The second mechanism,
supported by clinical observations and laboratory studies, is immune-
mediated suppression of marrow cells
Clinical presentation:
The  signs  and  symptoms  of  patients  presenting  with  aplastic
anemia are typically related to the decrease or absence of peripheral
blood cellular components. The clinical presentation ranges from
insidious to dramatic.
Hepatosplenomegaly, lymphadenopathy, or bone pain is less
common in patients with aplastic anemia.
Diagnostic Evaluation:
The hallmark of aplastic anemia is pancytopenia and a hypocellular
bone marrow. Because of the hypoproliferative marrow, the reticulocyte
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response is low or absent despite the anemia. Bone marrow aspiration and
biopsy must be performed to rule out other possible causes for
pancytopenia, such as MDS or leukemia. In normal bone marrow, 40% to
60% of the marrow space is typically occupied with hematopoietic cells
depending on the age of the person; by contrast, the bone marrow in
patients with aplastic anemia typically contains very few hematopoietic
cells and consists primarily of  fatty space and stromal cells.
MYELODYSPLASTIC SYNDROMES
The MDS are a group of clonal hematopoietic stem cell disorders
that are characterized by abnormal bone marrow differentiation and
maturation, which leads to bone marrow failure with peripheral
cytopenias, dysfunctional blood elements, and probability of leukemic
conversion. Most cases occur between the ages of 50 and 90 years. Most
cases are sporadic.
The disorders range from clonally derived (refractory) anemias to
oligoblastic myelogenous leukemia (refractory anemia with excess
blasts). The diseases share a propensity to (1) cytopenias, as a result of
inappropriate apoptosis, usually of late-stage marrow precursors, and (2)
multilineage dysmorphogenesis of blood cells. Red cells often have
striking poikilocytosis, anisocytosis, anisochromia, and basophilic
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stippling. The marrow usually contains increased erythroid precursors
with dysmorphic features, including nuclear distortions and scanty,
poorly hemoglobinized cytoplasm. Ringed sideroblasts are almost a
constant feature. Neutrophils have anomalies, including bilobed nuclei
and hypogranulated cytoplasm, in association with increased marrow
granulocyte precursors. Giant and microcytic platelets, often with
abnormal granulation, in the blood are associated with megakaryocytic
hyperplasia and atypical lobulation of the nucleus and decreased size of
megakaryocytes in the marrow. The bone marrow in MDS is typically
hypercellular or normocellular, although hypocellularity may also be
detected. It is important to distinguish hypocellular MDS from aplastic
anemia because the diagnosis dictates clinical management and
prognosis. A critical feature that identifies hypocellular MDS is an
associated clonal cytogenetic abnormality (such as deletions in
chromosome arms 5q and 7q).
The  syndrome  primarily  affects  older  women,  exhibiting  anemia
and hypercellular and dysmorphic erythropoiesis with lobulated
erythroblast nuclei and hypolobulated micromegakaryocytes but usually
normal or elevated platelet counts. It is the most indolent form of the
myelodysplastic syndrome with the lowest propensity to evolve into
AML. In the more progressive syndromes, leukemic blast cells are
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increased, cytopenias are more severe, and the disease has high morbidity
and mortality from infection and bleeding. Each of the syndromes has a
propensity to evolve into frank AML ranging from approximately 10 to
15 percent in the clonal (refractory) anemias to approximately 40 to 50
percent of patients with trilineage cytopenias and increased marrow blast
cells. Mortality from infection is a high risk in patients with severe
leucopenia.
Disorders of the hematopoietic system including lymphadenopathy,
anemia, leukopenia, and/or thrombocytopenia are common throughout
the course of HIV infection and  may be the direct result of  HIV,
manifestations of secondary infections and neoplasms, or side effects of
therapy.
Direct histologic examination and culture of lymph node or bone
marrow  tissue  are  often  diagnostic.  A  significant  percentage  of  bone
marrow aspirates from patients with HIV infection have been reported to
contain lymphoid aggregates, the precise significance of which is
unknown. Initiation of  HAART  lead to reversal of most hematologic
complications that are the direct result of HIV infection.
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CAUSES OF BONE MARROW SUPPRESSION IN PATIENTS
WITH  HIV  INFECTION
HIV infection
Mycobacterial infections
Fungal infections
B19 parvovirus infection
Lymphoma
Medications
Zidovudine
Dapsone
Trimethoprim/sulfamethoxazole
Pyrimethamine
5-Flucytosine
Ganciclovir
Interferon-?
Trimetrexate
Foscarnet.
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In patients  with SLE apart  from antibodies to double strand DNA
and anti-smith antibodies, antibodies that target each of the cellular blood
elements are also common. Anemia is present in about 50% of patients
and is multifactorial. It can be associated with a positive Coombs test or
microangiopathic hemolysis or reflect chronic disease (normochromic,
normocytic). Leukopenia, particularly lymphopenia, is observed, with the
lymphocyte count decreasing in the setting of increased disease activity.
Antibodies that bind to lymphocytes and neutrophils have been described,
and an increased tendency for lymphocytes to undergo spontaneous
apoptosis may contribute to lymphopenia. Idiopathic thrombocytopenic
purpura can be an early manifestation of SLE, and thrombocytopenia,
induced by antiplatelet antibodies, can sometimes lead to a life-
threatening risk for hemorrhage.
Our study attempts to find the common causes and clinical
presentation of patients with pancytopenia.
MATERIALS
&
METHODS
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MATERIALS AND METHODS
Study Design:
                           Prospective Cross-Control Study.
Study Population:
Patients admitted to general medical wards at
Government General Hospital, Chennai.
Inclusion criteria:
                          Patients admitted to general medical ward with
? Age > 13 yrs,
? Hb hemoglobin of less than 12 g per dL in women and less than 13
g per dL in men,
? WBC < 4000 cells/?l,
? Platelet count < 1,50,000 /?l.
Exclusion criteria:
? Patients with a known hematological condition
? Patients on cancer chemotherapy
? Patients who received blood transfusion.
Ethical Clearance:
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                           Obtained.
Informed Consent:
Obtained from all patients.
Methodology:
                         A total of 65 patients were identified over a period of
8months (jan 2010 – aug 2010 ) according to the above criteria and were
included in the study.
                        In all patients a detailed relevant history was taken
including the dietary history,  treatment history,  alcohol intake,drug
intake as well as radiation exposure. Meticulous clinical examination of
every patient was done for pallor, fever,bleeding tendencies, jaundice,
hepatomegaly, splenomegaly, sternal tenderness,  and lymphadenopathy.
                          Basic investigations were performed for each patient
including Haemoglobin, Total leukocyte count, Platelet count,
Reticulocyte count and Liver function tests.Absolute values including
packed cell volume (PCV), Mean corpuscular volume (MCV), mean
corpuscular haemoglobin (MCH) and mean corpuscular haemoglobin
concentration (MCHC) were calculated for every patient.Viral markers
(HBsAg,Anti HCV,HIV)were done in all patients.  Chest radiograph and
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abdominal ultrasonography were done all patients. Peripheral smear
examination and Bone marrow examination were done in all patients and
wherever required, a trephine biopsy  was  also  performed. Vit B12
levels , serum  folate levels, upper and lower gastrointestinal endoscopy
were done in selected patients.Also thyroid profile is done in selected
patients.
Statistical Analysis:
Data analysis was done with use of SPSS, version 13. Descriptive
statistics were used to calculate the frequency, mean, and standard
deviation. To examine the linear trend of the proportions, trend chi-square
was used and to find the test of association chi-square was computed.
Financial support:
Nil
Conflicts of interest:
None
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S.NO Parameter Method
1. Complete blood count Automated flow cytometry
2. ESR Westergren method
3. Urea GLDH/urease
4. Creatinine Picrate method
5. Serum albumin Bromocresol green
6. Serum bilirubin Calorimetric endpoint diazo
7. Total protein Biuret method
8. Serum Vitamin B12 Electro Chemi LuminescenceImmuno Assay
9. Serum Folate Electro Chemi LuminescenceImmuno Assay
10. HIV Enzyme Linked ImmunosorbentAssay
11. HbSAg Enzyme Linked ImmunosorbentAssay
12. HCV Enzyme Linked ImmunosorbentAssay
13. Serum T4 Chemi Luminescence ImmunoAssay
14. Serum TSH Chemi Luminescence ImmunoAssay
15. Occult blood in stools Standard guiac test
16. Serum ferritin Electro Chemi LuminescenceImmuno Assay
17. Serum iron Ferrozine  photometry
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NORMAL VALUES
Hemoglobin M: 13.3 – 16.2gms% F: 12.0 –15.8gms%
PCV M: 38.8 – 46.4 35.4 – 44.4
Total Count 3.54 – 9.06x 103/mm3
Platelet Count 165 – 415 x 103/mm3
MCV 80 – 100 fL
MCHC 32.3 – 35.9g/dL
MCH 26.7 – 31.9 pg/cell
ESR M: 0 -15mm/hr F: 0-20mm/hr
Reticulocyte count M: 0.8 – 2.3% F: 0.8 – 2.0 %
Creatinine M: 0.6 – 1.2mg/dl F: 0.5 – 0.9mg/dl
BUN 7 – 20 mgs/dl
Se.Iron 50 – 150µg/dl
Se.Vitamin B12 279 – 996 pg/ml
Se.Folate 5.4 – 18.0 ng/ml
Se.LDH 115-221 IU/L
Se.TSH 0.3 – 5.5 µIU/ml
Se.T4 0.7 – 1.8 ng/dl
Total Bilirubin 0.3 – 1.3 mgs/dl
Direct Bilirubin 0.1 – 0.4 mgs/dl
SGOT 12 – 38 U/L
SGPT 7 – 41U/L
Se.Alkaline phosphatase 33 – 96 U/L
Total Protein 6.7 – 8.6 gms/dl
Se.Albumin 3.5 – 5.5 gms/dl
Se.Ferritin M:29-248µg/L           F:10-150µg/L
OBSERVATIONS
&
RESULTS
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OBSERVATIONS & RESULTS
STUDY POPULATION CHARACTERISTICS:
A total no of 65 patients were found to have pancytopenia between
Jan 2010 and Aug 2010.
TABLE:1 SEX DISTRIBUTION
NO. OF
PATIENTS PERCENTAGE p - value
Males 35 53.85%
0.385
Females 30 46.15%
Total 65 100.00%
FIGURE: 1 SEX-WISE DISTRIBUTION OF  PATIENTS
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Among 65 patients included in our study, 35 (53.85%) patients
were male, and 30 (46.15%) patients were female, though it is not
statistically significant with p-value of 0.385.
TABLE:2 AGE AND SEX DISTRIBUTION OF STUDY
POPULATION
Age Group Males Females Total Percentage
Below 20 6 2 8 12.30%
21- 30 10 5 15 23.07%
31 – 40 9 7 16 24.62%
41 – 50 5 9 14 21.54%
Above  50 5 7 12 18.46%
Total 35 30 65 100.00%
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FIGURE: 2 DISTRIBUTION OF PATIENTS BASED ON AGE
Male preponderance is seen in patients < 30 yrs of age while
female preponderance is seen in age group above 40 yrs of age though
this finding is statistically insignificant (p – value of 0.545)
The age of the patients  ranged between 14 yrs and 60 yrs  with
maximum no of patients seen between 31 – 40 yrs of age with a slightly
male preponderance.
The Mean age of the patients included in the study is 37.12 mean
years, with S.D. of 10.2 years, with mean age of males being 33.51years
and females  41.33 years. No of patients were equally distributed  among
all age groups, though males were more common in younger age group.
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CLINICAL PRESENTATION:
TABLE: 3 CLINICAL FEATURES OF PATIENTS ACCORDING TO
VARIOUS ETIOLOGIES
DIAGNOSIS A B C D E F  G
MEGALOBLASTIC
ANEMIA 12 25 3 0 7 7 0
APLASTICANEMIA 14 16 2 12 1 1 0
HYPERSPLENISM 2 8 6 4 1 8 0
ACUTE LEUKEMIA 6 6 0 4 4 3 3
MYELODYSPLASTIC
SYNDROME 1 4 2 1 0 2 0
MYELOFIBROSIS 0 1 1 1 1 1 0
CONNECTIVE
TISSUE DISORDERS 2 2 1 0 0 1 0
HIV RELATED 1 1 0 0 0 0 0
INFECTION
INDUCED 2 1 0 0 1 0 0
TOTAL 40 65 15 22 15 23 3
A-FEVER
B-PALLOR
C-ICTERUS
D-BLEEDING
E-HEPATOMEGALY
F-SPLENOMEGALY
G-LYMPHADENOPATHY
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Pallor was present in almost all cases. Fever was the second  most
common presentation in our study as(40 out of 65 patients) 61.54% of
patients had fever during the course of illness which is stastically
insignificant with a p value of 0.063.
 FIG: 3 VARIOUS CLINICAL FEATURES  OF PATIENTS WITH
PANCYTOPENIA
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33.84% of patients (22) had bleeding manifestations, and are found
to have either aplastic anemia or acute leukemias which is stastically
significant(p vaue   0.009)
Icterus was present in 23.07% of the patients(15).Most of them had
chronic liver disease or megaloblastic anemia which is stastically
significant(p vaue <  0.001,significant at 5% level).
Liver was palpable in 15 (23.07%) of patients and was
predominantly seen in patients with megaloblastic anemia and leukemia
which is stastically significant(p vaue <  0.001,significant at 5% level).
Splenomegaly was found in 23 patients (35.38%); found in all
cases of hypersplenism, and in few cases of megaloblastic anemia, MDS,
and myelofibrosis which is stastically significant(p vaue <  0.018).
Lymphadenopathy was found only in 3 (4.62%) cases and  seen in
patients with acute leukemia which is stastically significant(p vaue <
0.001,significant at 5% level).
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PERIPHERAL SMEAR FINDINGS:
A detailed peripheral smear examination was done in all patients.
TABLE: 4 PERIPHERAL SMEAR FINDINGS ACCORDING TO
VARIOUS DIAGNOSIS
DIAGNOSIS A B C D E F  G  H
MEGALOBLASTIC  23 7 23 0 1 6 15 -
APLASTIC ANEMIA 4 - - - - - 1  9
HYPERSPLENISM - - - - - 4 - 8
ACUTE LEUKEMIA - - - 6 - - - 1
MDS 1 - - - - - - 3
MYELOFIBROSIS 1 - - - - - - 1
CTD - - - - - - - 2
HIV - - - - - - - 1
VIRAL INFECTION - - - - - - - 1
TOTAL 29 7 23 6 1 10 16 26
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A - Anisopoikilocytosis
B - Erythroblasts
C - Hypersegmented neutrophils
D - Immature WBC
E – Lymphocytosis.
F – Reticulocytosis
G- Macrocytes
H-Microcytic,hypochromic RBCs
FIG:4 PERIPHERAL SMEAR FINDINGS IN PATIENTS WITH
PANCYTOPENIA
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Anisopoikilocytosis and Hypersegmented neutrophils were the
predominant finding (92%) in cases of megaloblastic anemia; other
findings being erythroblasts, lymphocytosis, and reticulocytosis.
Anisopoikilocytosis was also found in few cases of aplastic
anemia. Peripheral blood WBC blasts were found in 4 cases of acute
leukemia and in a case of MDS.
Atypical lymphocytes  were  found in two cases of viral infection.
Pseudo Pelger Huet cells (hyposegmented neutrophils) were
present in two cases of myelodysplastic syndrome.
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VARIOUS ETIOLOGIES OF PANCYTOPENIA:
FIGURE: 5 DISTRIBUTION OF VARIOUS ETIOLOGIES OF
PANCYTOPENIA
The most common cause of pancytopenia in our study was
megaloblastic anemia (38.46%), followed by aplastic anemia (24.62%),
hypersplenism (12.31%). The other causes are acute leukemias (9.23%),
Myelodysplastic syndrome (6.15%), collagen vascular disorder (3.08%),
viral infection (3.08%), HIV (1.54%), and myelofibrosis (1.54%).
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TABLE: 5 DISTRIBUTION OF CAUSES OF PANCYTOPENIA
ACCORDING TO SEX
DIAGNOSIS MALE FEMALE TOTAL
MEGALOBLASTIC ANEMIA 11 14 25(38.46%)
APLASTIC ANEMIA 10 6 16(24.62%)
HYPERSPLENISM 6 2 8(12.31%)
ACUTE LEUKEMIA 2 4 6(9.23%)
MYELODYSPLASTIC
SYNDROME 3 1
4
(6.15%)
MYELOFIBROSIS 0 1 1(1.54%)
CONNECTIVE TISSUE
DISORDER 0 2
2
(3.08%)
HIV INFECTION 1 0 1(1.54%)
VIRAL INFECTION 2 0 2(3.08%)
TOTAL 35 30 65
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FIGURE: 6 DISTRIBUTION OF CAUSES OF PANCYTOPENIA
ACCORDING TO SEX
Megaloblastic anemia was more common in females (14)
compared to males (11) in our study. While Aplastic anemia is common
in males (10) than females (6); both of which are statistically significant.
Hypersplenism, MDS, viral infections were common in males;
while acute leukemias, myelofibrosis were common in females.
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MEGALOBLASTIC ANEMIA:
Mean age of patients with megaloblastic anemia is 39.32 yrs.
84 % of patients had macrocytosis; with a maximum of 127.3femtolitres;
16% of patients had normocytic anemia.
FIGURE 7: DISTRIBUTION OF MEGALOBLASTIC ANEMIA
ACCORDING TO SEX
56% of patients (14) with megaloblastic anemia are females, and
the remaining 44% are males (11).
84% of patients with megaloblastic anemia had MCV > 100
femtolitres; and 16% of them had MCV in normal range < 100
femtolitres.
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FIGURE 8: DISTRIBUTION OF PATIENTS ACCORDING TO
MCV
FIGURE 9: PERIPHERAL SMEAR FINDINGS IN PATIENTS
WITH MEGALOBLASTIC ANEMIA
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Anisopoikilocytosis (92%), and hypersegmented neutrophils (92%)
are the most common findings in peripheral smear of patients with
megaloblastic anemia.
FIGURE 10: CLINICAL FEATURES OF PATIENTS WITH
MEGALOBLASTIC ANEMIA
Pallor was present in all cases.  The other features were fever
(48%), icterus (12%), hepatomegaly (28%), and splenomegaly (28%).
21 patients had vitamin B12 deficiency and 4 had folate
deficiency.Among the 11 male patients with Megaloblastic anemia 7
were alcoholics,2 patients had abdominal surgeries,one patient had
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features of malabsorption and another one was a pure vegetarian.Among
14  female patients with Megaloblastic anemia 4 were diagnosed to have
hypothyroidism,2 patients had pernicious anemia.3 female patients were
pure vegeterians.another 2 patients had history of consumption of anti
epileptic drugs.
APLASTIC ANEMIA:
24.62% of patients had aplastic anemia. Of which 10(62.5%) were male
and 6(37.5%) were female.Mean age of patients with aplastic anemia is
33.43 yrs.Average Hb% of these patients is 4.80 gms%.
56.25%  of patients had  thrombocytopenia < 10,000 cells/cumm.
FIGURE 11: DISTRIBUTION OF APLASTIC ANEMIA
ACCORDING TO SEX
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68.75% of patients with aplastic anemia had MCV<100 femtolitres
 while 31.25% had MCV>100 femtolitres.
FIGURE 12: DISTRIBUTION OF PATIENTS WITH APLASTIC
ANEMIA ACCORDING TO MCV
FIGURE 13: CLINICAL FEATURES OF PATIENTs WITH
APLASTIC ANEMIA
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The various clinical features of patients with aplastic anemia were
pallor (100%), fever (87.5%), icterus (12.5%), bleeding (75%),
hepatomegaly (6.25%), and splenomegaly (6.25%).
HYPERSPLENISM
8 patients (12.31%) with pancytopenia were diagnosed to have
hypersplenism of which 6 were male and 2 were female patients.
Out of 8 patients 2(25%) had Extra Hepatic Portal Obstruction, while the
remaining 6 (75%) had Cirrhosis of liver leading to hypersplenism.
FIGURE 14: VARIOUS ETIOLOGIES OF HYPERSPLENISM
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ACUTE LEUKEMIA
6 patients (9.23%) was diagnosed to have acute leukemias;
4(66.7%) of them with acute myeloid leukemia; 2(33.3%) with acute
lymphoid  leukemia.out  of  the  6  patients  2  were  males  and  4  were
females.
FIG:15  DISTRIBUTION OF PATIENTS WITH LEUKEMIA
ACCORDING TO SEX
All of the patients with leukemia had blasts in their peripheral
smear.One of the patients had AML M1 type of leukemia.
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MYELODYSPLASTIC SYNDROME
MDS was diagnosed in 4 patients (6.15%); of which 3(75%) were
male, and 1 (25%) was female.
Mean age of these patients is 56.25yrs .Pseudo Pelger Huet
cells(Hyposegmented neutrophils) were present in two cases of MDS.
Erythroblasts were found in peripheral smear of one of these patients.
MYELOFIBROSIS
One (1.54%) female patient was diagnosed to have myelofibrosis.
VIRAL INFECTIONS
2 patients (3.08%) had features of systemic viral infection; their
peripheral smear showed atypical lymphocytes but no blasts.
          1 (1.54%) male patient was positive for HIV.
COLLAGEN VASCULAR DISORDER
2 patients (3.08%) were found to have Systemic lupus
erythematosis; both of them were young females.
Fig: 1 peripheral smear of a patient with megaloblastic anemia showing
anisopoikilocytosis with hypersegmented neutrophil.
Fig: 2 Bone marrow examination of a patient with megaloblstic anemia showing
hypercellular with increased erythropoiesis, larger megakaryocytes  with
hyperlobated nuclei
Fig: 3 Bone marrow examination of a patient with aplastic anemia showing
hypocellular marrow replaced by fat.
Fig: 4  Blood smear of a patient with Myelodysplastic Syndrome showing
hypogranulated eosinophils with hyposegmented nuclei.(Pseudo Pelger huet cells).
DISCUSSION
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DISCUSSION
Pancytopenia is a serious hematological problem which presents
with anemia, bleeding manifestations and infections. There are only a
limited number of studies from India on the frequency of various causes
of pancytopenia.The variation in the frequency of various entities causing
pancytopenia has been attributed to the differences in methodology and
stringency of diagnostic criteria, geographic area, period of
observation,genetic differences and exposure to various myelotoxic
agents. Our study included 65 patients and the age group of the patients
range from 14 to 60 years. Of these 30 were females and 35 were males.
The mean age of the patients is  37.12 years. Most male patients are under
30 years and females more than 40 years.
Analysis of the data observed in our study has shown the etiology
distribution of pancytopenia to be Megaloblastic anemia(25 cases;
38.46%), Aplastic anemia(16cases;24.62%),Hypersplenism(8
cases;12.31%),Acute leukemias(6 cases;9.23%),Myelodysplastic
syndrome(4 cases;6.15%),Myelofibrosis(1 case;1.54%),Connective tissue
disorder(2 cases;3.08%)HIV infection(1 case;1.54%)and Viral infection(2
cases;3.08%).
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Incidence  of  Megaloblastic anemia varies from 0.8 to 32.26%  in
various studies. In our study the incidence of Megaloblastic anemia is
38.46%. Similar results were obtained in the studies done by Kumar et
al1(22%) , Aziz et al2 (40.9%) , Savage et al 3,Iqbal et al7 . However the
study by Tilak et al4 showed the incidence to be 68%.
In our study, the predominant signs present in patients with
megaloblastic anemia were pallor(100%) followed by fever(48%),
hepatomegaly(28%), splenomegaly(28%) and icterus(12%).Similar
results  were  shown  in  the  studies  done  by  Tilak  et  al4 ,Khunger et
al5(pallor in 100% of patients with Megaloblastic anemia)and Aziz et
al2(pallor in 98% of patients with megaloblastic anemia).
In our study, 92% of Megaloblastic anemia patients had
hypersegmented neutrophils in their peripheral smear and 28% had
circulating megaloblasts.This is in concordance with the studies done by
Tilak et al4,Khunger et al5and Ishtiaq et al15.
Most  of  the  megaloblastic  anemia  in  our  study   were  due  to
Vitamin B12 deficiency (84%).16% were due to folate deficiency.Similar
results  were  shown in  the  study  done  by  Aziz  et  al2(77.77% of patients
had Vit B12 deficiency and33.33% had folate deficiency).
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In our study,84% of  patients with megaloblastic anemia had MCV
more than 100fl.16% had MCV less than 100 fl. The maximum MCV
noted was 127.3 fl.Megaloblastic anemia should be considered on top if
MCV is  greater  than  100  fl.Most  of  the  patients  had  increased  levels  of
serum iron and ferritin.Most of the precursor cells are destroyed in the
marrow due to ineffective erythropoiesis and therefore serum iron is not
utilized.Once treatment is started  with Vit B12 or folate the serum iron
and ferritin levels fall.
Bone marrow aspiration showed typical megaloblasts with sieved
chromatin and asynchronic nuclear cytoplasmic ratio.Though we have
done   bone  marrow   aspiration   for   all   patients   it  can  be  deferred  in
those cases presenting with hepatosplenomegaly and having
hypersegmented neutrophils and or circulating megaloblasts in their
peripheral smear.These patients can be put on a trial of hematinics with a
close hematologic follow up.
Megaloblastic anemia was present in all age groups.Among the 11
male  patients  with  megaloblastic  anemia  in  our  study   7  were  chronic
alcoholics and 2 patients had undergone abdominal surgeries(one patient
underwent surgery for peptic ulcer disease and another one ileal
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resection).One patient had loose stools along with loss of weight for more
than three months.Upper GI endoscopy showed erosions in the stomach
and Lower GI endoscopy revealed cryptitis with cryptic abscess
suggestive of Ulcerative colitis.One male patient was a pure vegetarian
with even no milk consumption.
In our study, there were 14 females with megaloblastic
anemia.Among them 4 patients  were diagnosed to have
hypothyroidism.Most of them were  above 50 years.One young female
presented with jaundice,anemia and fever.she was diagnosed to have Vit
B12 deficiency with features of hemolysis.2 female patients had atrophic
gastritis in upper GI scopy suggestive of Pernicious anemia confirmed by
histopathological examination.Of these two patients one had
arthralgias,myalgias and history suggestive of skin rashes.The other
patient had family history of similar illness. 3 female patients with
megaloblastic anemia were pure vegeterians. In two patients with
megaloblastic anemia there is a general decrease in the intake of food due
to poverty.  The higher prevalence of nutritional deficiency has been cited
for the increased frequency of megaloblastic anemia.2 patients had
history of consumption of antiepileptic drugs for a longer period with no
concomitant folate supplementation.
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The  incidence  of  Aplastic  anemia  varies  from  10%  to  52.7%  in
patients with pancytopenia in various studies. In our study the incidence
of Aplastic anemia is 24.61%.The mean age of the patients is 33.43
years.The incidence was more common in males(62.5%)   as compared
to females(37.5%).The most common presentation was pallor(100%)
followed by fever(87.5%) and bleeding(75%).One of the patients  with
Aplastic anemia  in our study had splenomegaly.This could be due to  the
repeated blood transfusions. It is the second most common cause of
pancytopenia in our study as shown by  Aziz et  al2(31.88%) , Savage et
al3, Khunger et al5(14%) .The study done by Kumar et al1 showed aplastic
anemia to be the most common cause of pancytopenia with 29.5%.
 In Aplastic anemia hematopoiesis fails. Blood cell counts are
extremely low and the bone marrow appears empty. 31.25% of patients
with Aplastic anemia had MCV more than 100 fl. 56.25% of patients had
MCV less than 100 fl . The platelet count was less than 10,000 in 56.25%
of patients.
Pathophysiology appears to be immune mediated. Aberrant
immune response may be triggered by environmental exposures to
chemicals,drugs,viral infections and endogenous antigens.Aplastic
anemia is more common in developing countries which may be attributed
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to the increased exposure to the toxic chemicals and increased availability
of over the counter medications.
Hypersplenism is the third most common cause (12.3%) of
pancytopenia in our study. Most of them are males. The study by Aziz et
al2 showed the incidence of hypersplenism in pancytopenic patients to be
6.81% .In our study,  25% of hypersplenism were due to Extra hepatic
portal  vein obstruction and 75% were due to chronic liver disease. One
of the patients  with chronic liver disease  was hepatitis C positive . The
bone marrow of this patient showed adequate hematopoiesis with mild to
moderate megaloblastic changes. This ruled out the possibility of
Hepatitis C induced myelosuppression.One of the patients was Hepatitis
B positive.
In our study,Chronic liver disease is the most common cause
associated with hypersplenism followed by extrahepatic portal vein
obstruction. This is in contrast to earlier studies done by Jitendar et al6 ,
Mohan et al7 where they found Chronic Malaria and Kala azar to be the
predominant causes of hypersplenism. Since those studies were done
more than a decade ago the better diagnosis and treatment of Malaria and
Kala azar might have lead to the decreased incidence of these diseases in
our study.
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Acute leukemia was found to be the fourth most common cause
(9.23%) of Pancytopenia in our study which is similar to a study
conducted by Savage et al3 who observed that the most common cause of
pancytopenia was megaloblastic anemia followed by aplastic anemia,
acute leukemia,
 AIDS and hypersplenism, and another study by Kumar et al1 who
reported the causes of pancytopenia in order of frequency as Aplastic
Anemia at 29.5%, megaloblastic anemia at 22%, Aleukemic Leukemia or
lymphoma (18%) and hypersplenism at 11.4%.
Of the 6 patients with acute leukemias, 4 had acute myeloid
leukemia, and 2 had acute lymphocytic leukemia.
The incidence of myelodysplastic syndrome is 6.15% in our study .
Most of the patients are above 50 years . It is a disease characterized by
ineffective hematopoiesis . It differs from AML by its increased apoptosis
in early stages. Hyposegmented neutrophils(Pseudo Pelger Huet cells)
were  seen  in  the  peripheral  smear  of  two  patients  with  MDS.
Hypercellularity of  bone marrow with abnormal cells confirmed the
diagnosis.In all the above patients malignancy,monoclonal gammopathies
were ruled out by appropriate investigations.Serum folate and vit B12
levels were normal in all the patients with MDS  in our study.
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The incidence of connective tissue disorder as a cause of
pancytopenia is 3.07%. One of the patients had autoimmune
myelofibrosis with autoimmune thyroiditis.
Myelofibrosis was diagnosed  in one patient(1.54%) with
pancytopenia. There was an  extensive marrow replacement by fibrosis.
There will be increasing splenomegaly  and  hepatomegaly due to
extramedullary hematopoiesis .The peripheral blood cells are low due to
decreased production from the marrow as well as due to hyperfunctioning
of  the spleen.
One middle aged patient was diagnosed as  having HIV induced
pancytopenia. But the incidence is low in our study compared to other
studies where the incidence ranges from 6 to 10%.This patient was first
diagnosed as having HIV in our centre and he was not on any drugs prior
to admission.His HCV status was negative and he had no evidence of any
lymphoproliferative disorder,tuberculosis or other viral infections.Since
all the causes were ruled out the patient was diagnosed to have HIV
induced pancytopenia.The bone marrow aspirate in this patient was
hypocellular,occasional megakaryocyte with bare nuclei seen.There was a
moderate reduction in erythroid progenitors with dyserythropoiesis,mild
to moderate reduction in granulocyte progenitors with normal maturation,
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Lymphocytes 22%,transformed  lymphocytes present,increased
Reticuloendothelial cells  with hemophagocytosis.
2 of our patients presented with systemic viral infection were found
to have pancytopenia. They also had atypical lymphocytes in their
peripheral smear. This entity should be considered in patients in whom
other causes of pancytopenia has been ruled out and having signs of viral
infection.
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LIMITATIONS OF THE STUDY
? The major  limitation  of  our  study  is  the  small  number  of  subjects
we have included in our study.
? Antibodies to Intrinsic factor was not done in pernicious anemia
causing Megaloblastic anemia.
? Trephine biopsy evaluation was not done in all patients.Therefore
more definitive evaluation of cellularity and exclusion of focal
lesions could not be done.
? There has been a very limited follow up of patients and therefore
response to therapy could not be assessed.
CONCLUSION
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CONCLUSION
? Megaloblastic anemia is  the most common cause of pancytopenia
in our setting.
? This probably indicates the poor nutritional status of the general
population in our community.
? All patients with pancytopenia should be sought for megaloblastic
anemia as it is a potentially treatable condition.
?  Physicians should have a high index of suspicion for Vitamin B12
deficiency when dealing with patients presenting with symptoms of
anemia such as pallor and weakness and/or diagnosed with
pancytopenia on further workup.
? The finding of hypersegmented neutrophils in the peripheral smear
will guide in the diagnosis of megaloblastic anemia.
?  Bone marrow aspiration can  be deferred in those cases presenting
with hepatosplenomegaly and having hypersegmented neutrophils
and or circulating megaloblasts in their peripheral smear.These
patients can be put on a trial of hematinics(Vit B12/folate) with a
close hematologic follow up.
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? Aplastic anemia is the second most common cause of pancytopenia
in our study.
? The blood counts were extremely low in patients with aplastic
anemia.
? Hypersplenism is an important cause of pancytopenia in our
setting.
? Hypersplenism should be sought as a cause of pancytopenia in
patients with chronic liver disease especially alcoholics.
? Myelodysplastic syndrome is a common cause of pancytopenia in
the elderly population.
? After  the  common  causes  have  been  ruled  out  patient  should  be
evaluated for rare causes like HIV infection, systemic viral
infection, connective tissue disorders, and myelofibrosis.
? Peripheral smear and bone marrow examination would help in
identifying the etiology of pancytopenia in almost all patients.
? A Comprehensive evaluation of pancytopenia with a clinico
laboratory correlation would help in the appropriate management
of potentially treatable conditions.
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                             RECOMMENDATIONS
? Bone marrow  aspiration  can  be deferred in those cases presenting
with hepatosplenomegaly and having hypersegmented neutrophils
and or circulating megaloblasts in their peripheral smear.These
patients can be put on a trial of hematinics(Vit B12/folate) with a
close hematologic follow up.
? After ruling out the common diseases causing pancytopenia
patients should be investigated for less common conditions like
connective tissue disorders etc.
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ANNEXURES
A STUDY ON THE CLINICAL AND ETIOLOGICAL PROFILE OF
PATIENTS WITH PANCYTOPENIA
PROFORMA
Name:          Age:       Sex:                       OP.NO:
Address:                              Ph.No:
Presenting Complaints:
Easy fatiguability:                                                  Fever/chills & rigor:
Dyspnoea:                                                              Giddiness:
Jaundice:                                                                Abdominal distension:
Lymphadenopathy:
Purpura/Skin rash:                                                  Pedal edema:
Loss of Wt:                                                            Loss of Appetite:
Night Sweats:                                                          Bone Pain:
Bleeding Tendency: Gum bleed/Hematamesis/ Malena/Bleeding PR
Purpura/ Skin rash:
Cough/ burning micturition/loose stools:
Drug intake:
Alcohol intake/smoking:
Co-morbid Illness:  DM:        HT:    TB:      Cardiac illness:       any
malignancy:
Menstrual h/o:  undue bleeding PV:
h/o previous treatment/ surgery:
others if any:
EXAMINATION:
Fever:
Pallor:                                                              Jaundice:
Lymphadenopathy:                                        Cyanosis:
Clubbing:                                                       Pedal edema:
Purpura/Petechiae/Ecchymosis:
Sternal tenderness:                     Others:
CVS:
RS:
Abdomen:
Genitals:
Per rectal / pelvic examination:
INVESTIGATIONS  FOR ALL PATIENTS:
CBC
HB%:                 PCV:                  ESR:
Reticulocyte Index:
TC:        P:      L:      E:     B:      M:
Platelets:
Occult Blood in Stools:
Blood  sugar:
RFT:   Urea:                                Creatinine:
LFT: Tot.bilirubin:                 Direct:                SGOT:            SGPT:
Alkaline phosphatase:
Total Protein:                                             Serum Albumin:
Serum  LDH:
ELISA for HIV:
HBsAg:                                                       Anti-HCV:
X-RAY CHEST:
ECG:
USG-Abdomen:
Serum B12 level:
Serum Folate:
PT:                                      INR:                           aPTT:
Peripheral Smear Study:
Bone Marrow Study:
Upper GI scopy:
Lower GI scopy
Serum Electroporesis:
Se.Ferritin:
Others:
FINAL DIAGNOSIS:
MASTER CHART
S.NO AGE SEX FEVER PALLOR
ICTE
RUS
BLEED
WT
LOSS
ANORE
XIA
LIVER
SPLE
EN
LYMPHN
ODES
DYSP
NEA
ALCO
HOL
FOOD
HABITS
SURG
ERY HB PCV TC DC PLATELET MCV MCH MCHC RPI
1 17 F YES YES YES NO NO NO NO NO NO YES NO MIXED DIET NO 2.8 9 800 P74L23E3 5000 125 33.4 34.2 2.60%
2 48 M YES YES NO NO NO YES NO NO NO YES NO MIXED DIET YES 4.8 14 2500 P55L36M9 44000 93.9 32.7 34.8 0.90%
3 25 M NO YES YES YES YES YES NO YES NO YES YES MIXED DIET NO 9.2 29 1700 P71L20M9 28000 87.4 26.5 28.7 2.30%
4 40 F YES YES YES NO NO YES NO YES NO YES NO MIXED DIET NO 5 15 400 P60L20 19000 88.2 27.1 28.6 0.70%
5 14 M YES YES NO NO NO YES YES NO YES YES NO MIXED DIET NO 5.1 16 4000 P47L57E2 98000 91.1 28.9 31.5 1.50%
6 45 F YES YES NO YES NO NO NO NO NO YES NO MIXED DIET NO 3.8 12 2500 P23L71M6 10000 92.1 29.9 32.5 0.40%
7 23 F YES YES YES NO NO NO NO YES NO NO NO MIXED DIET NO 5.1 19 2600 P64l21e5 86000 74.2 20.2 27.3 2.80%
8 18 M YES YES NO NO YES YES YES YES YES YES NO MIXED DIET NO 7.4 23 500 TOO LOW 18000 88.4 27.3 29.7 1.40%
9 14 M YES YES NO YES YES YES NO NO NO YES NO MIXED DIET NO 3.9 12 1900 P14L82M4 2000 91.7 28.9 31.6 0.60%
10 27 M NO YES YES NO NO YES YES NO NO NO YES MIXED DIET NO 6.7 20 3100 P50L32E12M6 86000 104.7 35.3 33.7 0.70%
11 40 F YES YES NO YES NO YES NO NO NO YES NO MIXED DIET NO 2.1 6 2700 P54L45 4000 88.9 29.2 32.8 1.50%
12 21 M YES YES NO NO NO NO NO NO NO NO NO MIXED DIET NO 6.3 27 1700 P77L23 51000 77.5 23.4 26.5 1.90%
13 54 M YES YES NO NO YES YES NO NO NO YES YES MIXED DIET NO 2.7 9 3400 P48L42M3 120000 81.1 25.2 29.7 1.40%
14 23 M YES YES NO NO NO NO NO NO NO NO YES MIXED DIET NO 8 27 3400 P34L62 83000 93.2 27.4 29.4 1.00%
15 21 F YES YES NO YES YES YES NO NO NO YES NO VEGETERIAN NO 3.4 11 3400 P26L74 5000 97.3 30.1 30.9 0.50%
16 39 M NO YES YES NO YES YES NO YES NO YES YES MIXED DIET NO 3.6 14 8000 P65L30E05 8000 81.5 27.5 29.2 2.50%
17 60 F NO YES NO NO YES YES NO YES NO NO NO MIXED DIET NO 6.7 24 2300 P24L66M6E2 31000 97.7 20.1 25.9 0.90%
18 25 F YES YES NO YES YES YES NO NO NO NO NO MIXED DIET NO 10.3 30 2800 P76L23 5000 88.4 28.4 30.4 1.10%
19 60 M NO YES NO NO YES YES NO NO NO YES NO MIXED DIET NO 6.2 19 2400 P29L63 40000 91 28.3 30.3 0.70%
20 25 M YES YES NO NO NO YES NO NO NO YES NO MIXED DIET NO 2.9 9 1500 p51l33e16 10000 122.2 40.3 33 0.30%
21 29 M YES NO NO NO NO YES YES NO NO NO NO MIXED DIET NO 11.4 34 3200 P62L36E2 48000 89.2 26.4 28.9 2.10%
22 60 F NO YES NO NO NO NO NO NO NO NO NO MIXED DIET NO 6.9 21 3400 P70L22M8 86000 101 34 33.7 1.40%
23 38 M YES YES NO YES YES YES NO NO NO YES YES MIXED DIET NO 3.2 10 1700 P33L67 2000 100 32.7 32.5 0.20%
24 50 F NO YES NO NO NO NO NO NO NO NO NO MIXED DIET NO 7.2 21 3000 P45L47E8 94000 109.9 37.7 34.3 0.90%
25 33 M YES YES NO NO NO NO YES NO NO NO YES MIXED DIET NO 4.3 17 3400 P67L33 118000 108.3 29.5 31.1 0.70%
26 25 M NO YES NO YES YES YES NO YES NO NO NO MIXED DIET NO 11.4 35 3400 P70L21 E9 90000 94.5 24.4 27.8 2.60%
27 35 M NO YES NO NO NO YES NO NO NO NO YES MIXED DIET NO 5.7 18 2700 P23L77 39000 111.7 35.2 31.5 0.70%
28 40 F NO YES NO YES YES YES YES NO NO YES NO VEGETERIAN NO 1.6 5 2200 P23L77 4000 82.8 27.6 33.3 0.20%
29 58 M NO YES YES YES YES YES NO YES NO YES YES MIXED DIET NO 5.4 23 2600 P45L54 111,000 73.3 17.4 23.7 1.10%
30 55 F NO YES YES YES YES NO YES YES NO YES NO MIXED DIET NO 3.6 16 2800 P54L30E16 105000 86.3 27.9 29.1 0.60%
31 53 F YES YES NO NO NO NO NO NO NO NO NO MIXED DIET NO 9.2 33 3200 P57L34E4M5 121000 91.5 26.9 29.6 0.80%
32 25 F YES YES NO YES YES YES YES YES NO YES NO MIXED DIET NO 8.8 26 2600 P35L65 6000 92.4 27.1 29.7 1.40%
33 17 M YES YES YES NO NO YES NO YES NO NO NO VEGETERIAN NO 7.3 25 3100 P53L33M4 119000 105.8 31.1 33.2 1.10%
S.NO AGE SEX FEVER PALLOR
ICTE
RUS
BLEED
WT
LOSS
ANORE
XIA
LIVER
SPLE
EN
LYMPHN
ODES
DYSP
NEA
ALCO
HOL
FOOD
HABITS
SURG
ERY HB PCV TC DC PLATELET MCV MCH MCHC RPI
34 15 M YES YES NO YES YES NO NO NO NO YES NO MIXED DIET NO 5.1 16 2500 P25L75 12000 88.6 29 32.7 0.10%
35 50 F YES YES NO NO YES YES YES YES NO NO NO MIXED DIET NO 6.7 21 2900 P52L40M8 81000 104.8 31.5 33.4 1.00%
36 36 F NO YES NO NO YES YES YES YES NO YES NO MIXED DIET NO 5 17 3200 P69L22E4 96000 109.6 32.1 29.2 1.30%
37 28 F YES YES NO NO YES YES NO NO NO YES NO MIXED DIET NO 10.2 30 2500 P67L27M4 90000 88.2 28.3 31.7 1.20%
38 45 F YES YES YES NO YES YES YES YES NO NO NO MIXED DIET NO 5.4 21 2300 P58L28M4 78000 101.5 28.1 29.9 1.80%
39 42 M YES YES NO NO NO NO NO NO NO NO NO MIXED DIET NO 5.5 18 1100 P30L56M14 18000 97.7 31.1 31.8 0.10%
40 42 F NOYES YES NO NO NO YES NO YES NO NO NO MIXED DIET NO 10.4 33 3400 P55L28M17 25000 110.4 35 31.7 0.20%
41 35 M YES YES NO NO YES YES NO NO NO NO YES MIXED DIET NO 9.7 32 3100 P71L18E01 50000 103.9 29.7 31.9 1.20%
42 18 F YES YES NO NO NO YES YES YES NO NO NO MIXED DIET NO 2.2 10 2000 P43L53M4 47000 106.8 36.6 33.9 0.70%
43 26 M YES YES YES YES NO NO NO NO NO YES NO VEGETERIAN NO 3.6 10 2000 P24L76 10000 79.2 27.5 34.7 0.40%
44 45 F YES YES NO NO NO NO NO NO NO NO NO VEGETERIAN NO 5 21 2900 P61L28M4 111000 114.2 36.8 34.9 0.90%
45 52 F NO YES NO NO YES YES NO NO NO YES NO MIXED DIET NO 3.3 11 2300 P78L32 4000 111.5 34.4 30.8 0.60%
46 35 M YES YES NO YES NO YES NO NO NO YES NO MIXED DIET NO 5 16 2900 P47L49E4 6000 97.6 30.5 31.3 0.10%
47 39 F YES YES NO NO YES YES NO NO NO NO NO MIXED DIET NO 7.4 29 3400 P57L25E10 75000 119.4 33.9 28.4 0.90%
48 55 F NO YES NO NO NO NO NO NO NO NO NO MIXED DIET NO 6.9 22 3100 P50L28E22 71000 103.5 32.7 33.8 0.80%
49 31 M NO YES NO NO NO NO NO NO NO YES NO MIXED DIET NO 3.9 13 3300 P44L50ATY4 38000 127.3 39.4 31 1.00%
50 34 M NO YES NO NO YES YES NO YES NO NO NO MIXED DIET NO 8.9 28 3900 P56L35E3 80000 87.9 27.1 30.5 2.20%
51 50 M YES YES NO YES NO YES NO NO NO YES YES MIXED DIET NO 6.1 19 3600 P45L49E6 40000 83.2 26.3 31.6 0.30%
52 50 F NO YES NO NO YES YES NO NO NO YES NO MIXED DIET NO 4.5 19 2600 P48L38M10 128000 67.7 16 23.6 0.90%
53 43 M NO YES YES YES YES YES NO YES NO YES YES MIXED DIET NO 6 22 2100 P41L30M34 85000 75.5 21.4 24.7 1.90%
54 26 M YES YES NO YES NO NO NO NO NO YES NO MIXED DIET NO 2.7 8 1400 P24L76 8000 81.6 27.6 33.8 0.30%
55 36 F NO YES NO NO YES YES YES YES NO YES NO VEGETERIAN NO 6.6 21 2900 P70L13E4 69000 113.5 32.7 34.2 0.80%
56 53 M NO YES NO NO NO YES NO NO NO NO YES MIXED DIET NO 3.5 12 3100 P51L35E10 79000 108.3 31.1 32.2 1.20%
57 40 F YES YES YES NO NO NO NO NO NO NO NO MIXED DIET NO 9.7 31 3200 P29L68M3 20000 107.4 34 31.7 0.50%
58 27 M NO YES NO NO YES YES NO NO NO NO NO MIXED DIET YES 6.8 25 3100 P59L39E2 65000 111.3 32.3 34.1 0.90%
59 38 M YES YES NO NO YES YES YES YES NO YES YES MIXED DIET NO 4.1 13 2000 P60L33E7 95000 112.7 34.7 30.8 1.20%
60 60 F YES YES NO YES YES YES NO NO NO YES NO MIXED DIET NO 7.4 23 2000 P12L78 15000 93 30.2 32.5 0.20%
61 57 M YES YES YES NO NO YES NO YES NO YES YES MIXED DIET NO 8.8 25 3500 P62L30M6E2 44000 95.5 29.6 30.7 1.00%
62 45 F YES YES NO YES YES YES YES YES YES NO NO MIXED DIET NO 3.4 11 700 TOO LOW 1000 91.1 28.4 29.5 1.50%
63 16 M YES YES NO YES NO YES NO NO NO NO NO MIXED DIET NO 2.6 9 3500 P50L50 16000 114 33.3 29.2 0.20%
64 42 M NO YES YES YES YES YES NO YES NO YES YES MIXED DIET NO 3 9 1800 P35L49 50000 93.7 29.1 31.1 1.40%
65 45 F F YES NO NO NO YES NO NO NO NO NO VEGETERIAN NO 7.1 21 3500 P56L39E5 85000 112.2 32.4 28.9 0.60%
S.No LDH TB OT PT ALP TP
STOOL OCCULT
BLOOD HIV
VIRAL
MARKERS USG ABDOMEN UPPER GI ENDOSCOPY
SE.
IRON
SE
FERRITIN B12 FOL
1 1720 3.9 88 84 84 6 NO NEG NEG NORMAL NORMAL STUDY 234 170 140 6.5
2 556 0.8 32 44 51 6.2 NO NEG NEG NORMAL GASTRIC EROSIONS 345 256 185 7.2
3 230 5.5 260 185 275 4.6 POSITIVE NEG NEG SPLENOMEGALY,CIRRHOSIS  ESOPHAGEAL VARICES+ 65 90
4 354 2.4 124 135 155 5.1 NO NEG NEG SPLENOMEGALY NORMAL STUDY
5 145 1 35 45 51 4.9 NO NEG NEG HEPATOMEGALY
6 97 0.6 45 25 35 5.5 POSITIVE NEG NEG NORMAL
7 209 2 160 186 155 6.9 POSITIVE NEG NEG CLD,SPLENOMEGALY ESOPHAGEAL VARICES+ 120 95
8 178 0.7 77 65 45 4.9 NO NEG NEG HSM+,LYMPHADENOPATHY
9 78 0.9 33 35 54 5.2 NO NEG NEG NORMAL
10 453 1.8 66 76 102 5.8 NO NEG NEG MILD HEPATOMEGALY PANGASTRITIS,DUODENITIS 170 290 196 6.9
11 156 1.4 99 103 123 5.1 NO NEG NEG NORMAL
12 122 0.6 22 38 45 5.2 NO NEG NEG NORMAL
13 256 1.2 55 65 76 5.3 NO POS NEG NORMAL NORMAL STUDY 78 56
14 765 0.7 45 41 32 5.9 NO NEG NEG NORMAL PANGASTRITIS,DUODENITIS 235 305 290 4.1
15 125 0.7 22 32 45 6.1 POSITIVE NEG NEG NORMAL
16 176 6.5 235 350 285 4.8 POSITIVE NEG HBsAg+ SPLENOMEGALY,CIRRHOSIS ESOPHAGEAL AND GASTRIC VARICES 75 105
17 890 0.8 67 76 83 5.8 NO NEG NEG MILD SPLENOMEGALY NORMAL STUDY 245 185 213 7.1
18 345 1.1 53 45 60 6.1 NO NEG NEG NORMAL
19 567 1.8 45 45 54 5.6 NO NEG NEG NORMAL 170 250 330 11.3
20 90 1.1 34 23 45 5.9 POSITIVE NEG NEG NORMAL
21 231 0.5 10 24 35 6.1 NO NEG NEG MILD HEPATOMEGALY
22 550 1 35 35 75 5.6 NO NEG NEG NORMAL NORMAL STUDY 165 176 189 9.2
23 120 0.8 19 22 35 6.2 NO NEG NEG NORMAL
24 678 0.6 31 26 43 5.1 NO NEG NEG NORMAL NORMAL STUDY 250 185 232 9.7
25 345 0.9 83 92 45 5.3 POSITIVE NEG NEG MILD HEPATOMEGALY EROSIVE GASTRITIS 185 297 187 10.4
26 136 1.1 120 145 134 5.3 NO NEG NEG SPLENOMEGALY ESOPHAGEAL VARICES+ 87 98
27 478 0.5 42 55 45 5.7 NO NEG NEG NORMAL EROSIVE GASTRITIS 176 355 231 9.4
28 134 0.7 33 22 40 6.1 NO NEG NEG MILD HEPATOMEGALY
29 378 0.9 45 34 56 5.5 NO NEG NEG SPLENOMEGALY 125 220 420 9.9
30 104 1.1 40 35 40 5.7 NO NEG NEG SPLENOMEGALY 134 156
31 778 0.9 44 34 35 5.2 NO NEG NEG NORMAL NORMAL STUDY 199 175 245 9.9
32 173 0.8 70 65 64 5.1 NO NEG NEG HEPATOSPLENOMEGALY
33 687 2.1 99 101 123 6.1 NO NEG NEG MILD SPLENOMEGALY NORMAL STUDY 194 290 199 10.2
S.No LDH TB OT PT ALP TP
STOOL OCCULT
BLOOD HIV
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SE.
IRON
SE
FERRITIN B12 FOL
34 117 0.6 22 25 35 6.1 POSITIVE NEG NEG NORMAL
35 279 0.8 24 32 45 5.7 NO NEG NEG NORMAL NORMAL STUDY 150 185 201 6.2
36 525 1.1 45 54 65 5.9 NO NEG NEG MILD HEPATOSPLENOMEGALY NORMAL STUDY 165 156 340 4.2
37 245 0.7 35 25 45 4.9 NO NEG NEG NORMAL NORMAL STUDY 87 189
38 184 4.5 255 215 325 5.1 NO NEG ANTI HCV + HEPATOSPLENOMEGALY,PHT ESOPHAGEAL VARICES,GASTRITIS 96 123
39 112 1.2 43 40 53 5 POSITIVE NEG NEG NORMAL
40 95 0.9 22 33 54 6.1 NO NEG NEG MILD SPLENOMEGALY
41 420 1.1 85 75 92 5.9 POSITIVE NEG NEG NORMAL PANGASTRITIS,DUODENITIS 201 355 179 7.4
42 643 0.7 35 45 52 5.5 NO NEG NEG HEPATOSPLENOMEGALY ATROPHIC GASTRITIS. 168 176 142 5.6
43 118 2.5 88 94 105 5.2 NO NEG NEG NORMAL
44 665 0.6 44 53 34 5.4 NO NEG NEG NORMAL NORMAL STUDY 211 197 156 6.1
45 394 0.8 25 25 35 5.1 NO NEG NEG NORMAL NORMAL STUDY 176 188 440 3.4
46 101 0.4 17 24 35 5.7 POSITIVE NEG NEG NORMAL
47 756 0.8 34 45 52 5.4 NO NEG NEG NORMAL ATROPHIC GASTRITIS. 134 120 162 6.4
48 661 0.9 54 45 67 5 NO NEG NEG NORMAL NORMAL STUDY 183 211 220 9.2
49 290 0.6 25 35 42 5.1 POSITIVE NEG EG NORMAL GASTRITIS 175 299 165 11.1
50 220 0.8 157 187 206 5.6 POSITIVE NEG NEG SPLENOMEGALY ESOPHAGEAL AND FUNDAL VARICES 55 101
51 135 0.8 40 43 35 5.2 POSITIVE NEG NEG NORMAL
52 890 0.7 22 30 28 5.4 NO NEG NEG NORMAL 165 121 345 8.2
53 320 5.2 167 289 356 4.5 NO NEG NEG SPLENOMEGALY,CIRRHOSIS ESOPHAGEAL VARICES+,PANGASTRITIS 145 99
54 145 1.2 33 44 40 5.3 NO NEG NEG NORMAL
55 990 1.1 45 55 52 6.2 NO NEG NEG HEPATOSPLENOMEGALY NORMAL STUDY 201 190 155 9.2
56 1034 0.8 105 163 171 5.6 NO NEG NEG NORMAL PANGASTRITIS,DUODENITIS 177 234 391 3.9
57 125 3.2 134 156 106 5.2 POSITIVE NEG NEG NORMAL
58 967 0.7 25 35 45 5.4 NO NEG NEG NORMAL GASTIC EROSIONS 164 246 211 7.9
59 927 0.9 94 83 122 5.2 NO NEG NEG MILD HEPATOSPLENOMEGALY PANGASTRITIS,DUODENITIS 171 288 181 12.2
60 118 0.5 16 19 25 6.1 NO NEG NEG NORMAL
61 885 1.2 44 45 67 4.9 NO NEG NEG NORMAL 189 250 356 10.2
62 201 0.8 35 40 45 4.9 NO NEG NEG HEPATOSPLENOMEGALY
63 101 0.7 25 25 40 5.2 POSITIVE NEG NEG NORMAL
64 196 3.8 256 345 325 4.6 NO NEG NEG SPLENOMEGALY,CIRRHOSIS ESOPHAGEAL VARICES+,GASTRITIS 144 55
65 765 0.5 15 35 45 5.5 NO NEG NEG NORMAL NORMAL STUDY 256 195 241 10.2
S.NO. T4 TSH PERIPHERAL SMEAR
1 1.2 2.35 ANISOPOIKILOCYTOSIS+,MACROCYTIC RBC S,HYPERSEGMENTED NEUTROPHILS+,RETICS INCREASED
2 1.4 1.34 MACROCYTIC/NORMOCYTIC RBC S,ANISOPOIKILOCYTOSIS,HYPERSEGMENTED NEUTROPHILS+
3 MICROCYTIC HYPOCHROMIC RBCS.
4 MICROCYTIC/HYPOCHROMIC
5 MYELOID BLASTS 85% PRESENT
6 PANCYTOPENIA
7 MICROCYTIC/HYPOCHROMIC
8 MICROCYTIC HYPOCHROMIC RBCS,PLATELETS DECREASED,WBCS DECREASED,BLASTS+
9 SEVERE PANCYTOPENIA
10 0.75 0.91 MACROCYTIC RBC S,ANISOPOIKILOCYTOSIS,PLATELETS DECREASED,HYPERSEGMENTED NEUTROPHIL+,TEAR DROP CELLS,
11 MYELOID BLASTS+
12 MICRO HYPO RBCS,TARGET CELLS
13 MICRO,HYPO rbcs NORMO RBCS
14 0.56 1.21 ANISOPOIKILOCYTOSIS,PLATELETS DECRESED,LYMPHOCYTOSIS,HYPERSEGMENTED NEUTROPHILS+
15 MICROCYTIC/HYPOCHROMIC RBCs PRESENT
16 micro,hypo rbcs target cells,reticulocytosis.
17 0.09 6.25 MACROCYTIC RBCS,ANISOPOIKILOCYTOSIS,HYPERSEGMENTED NEUTROPHILS+
18 BLASTS 10%,TLC DECREASED.PLT DECREASED
19 PANCYTOPENIA,OCC ATYPICAL CELLS,ANISOPOIKILOCYTOSIS,GIANT PLATELETS.
20 MACROCYTIC RBCS,DECREASED WBCS,
21 NORMO,NORMO RBCS
22 0.41 3.23 MACROCYTIC RBC S,ANISOPOIKILOCYTOSIS,PLATELETS DECREASED,ERYTHROBLAST+,ROULEAUX FORMATION+,HYPERSEGMENTED POLYMORHS+
23 MICROCYTIC/HYPOCHROMIC
24 0.06 7.23 MACROCYTIC/NORMOCYTIC RBC S,ANISOPOIKILOCYTOSIS,FEW ELLIPTOCYTOSIS,HYPERSEGMENTED NEUTROPHILS+,INCREASED RETIC
25 1.23 3.45 MILD ANISOPOIKILOCYTOSIS,SMALL PLATELET CLUMPS+,HYPERSEGMENTED NEUTROPHILS+
26 MICRO HYPO/NORMO RBCS,RETICULOCYTOSIS+
27 1.56 4.35 MACROCYTIC RBCS, FEW TARGET CELLS,ANISOPOIKILOCYTOSIS,HYPERSEGMENTED NEUTROPHILS+,PLATELETS DECREASED,WBC MOD RED.
28 rbcs sparsely distributed,severe mchc with anisopoikilocytosis,wbcs dec,platelets dec.
29 MICRO HYPO/NORMO RBCS
30 MICRO HYPO/NORMO RBCS,ANISOPOIKILOCYTOSIS,TEAR DROP SHAPED CELLS.
31 0.05 8.34 NORMO/MACROCYTIC RBCS,ANISOPOIKILOCYTOSIS,ERYTHROBLASTS,HYPERSEGMENTED NEUTROPHILS+,PLT LOW,HSPS+
32 MYELOID BLASTS+,TLC DECREASED,PLT DECREASED
33 1.25 3.14 NORMO/MACROCYTIC RBCS,ANISOPOIKILOCYTOSIS,ERYTHROBLASTS+,PLT LOW,HYPERSEGMENTED POLYMORPHS+
S.NO. T4 TSH PERIPHERAL SMEAR
34 NORMO/HYPO RBCS
35 1.13 2.91 POIKILOCYTOSIS+,MILD ROULEAUX FORMATION,HYPERSEGMENTED NEUTROPHILS,PLATELETS DECREASED.
36 1.34 3.96 MACROCYTIC RBCS,HYPERSEGMENTED NEUTROPHILS+,ERYTHROBLASTS,INCREASED RETIC COUNT,PLT DECREASED
37 MICRO HYPO/NORMO RBCS
38 MICRO HYPO/NORMO RBCS
39 severe microcytic hypochromic rbcs,anisopoikilocytosis,wbc decreased,platelets decreased
40 NCNC rbcs,mild anisopoikilocytosis,tear drop cells seen.wbc dec,plt dec.
41 0.81 3.19 NORMOCYTIC/NORMOCHROMIC,MACROCYTIC RBCS,ANISIPOIKILOCYTOSIS,HYPERSEGMENTED NEUTROPHILS+,PLT DECREASED
42 1.52 2.76 ANISOPOILKILOCYTOSIS,RETICULOCYTOSIS,HYPERSEGMENTED NEUTROPHILS+,PLT DECREASED,WBC DECREASED
43 MICRO,HYPO RBCS
44 1.45 3.56 MACROCYTES+,ERYTHROBLASTS+,HYPERSEGMENTED POLYMORPHS,ANISOPOIKILOCYTOSIS+.PLATELETS DECREASED,CLUMPS+
45 1.23 2.91 ANISOPOIKILOCYTOSIS,MACROCYTES
46 MICRO,HYPO RBCS
47 0.91 4.1 ANISOPOIKILOCYTOSIS,PLATELETS DECRESED,HYPERSEGMENTED NEUTROPHILS+
48 0.12 10.5 ANISOPOIKILOCYTOSIS,PLATELETS DECRESED,HYPERSEGMENTED NEUTROPHILS+
49 1.67 2.96 MACROCYTES+,ERYTHROBLASTS+,HYPERSEGMENTED POLYMORPHS,ANISOPOIKILOCYTOSIS+.PLATELETS DECREASED,CLUMPS+
50 MICRO HYPO RBCS TARGET CELLS,RETICULOCYTOSIS+
51 microcytic hypochromic rbcs,platelets decreased,wbc s decreased.
52 gross microcytic hypochromic rbcs,platelets mildly dec,tlc mod dec,atypical cells.
53 MICROCYTIC HYPOCHROMIC RBCS,RETICULOCYTOSIS+.
54 microcytic hypochromic rbcs,platelets decreased,wbc s decreased.
55 1.58 4.1 ANISOPOIKILOCYTOSIS,PLATELETS DECRESED,HYPERSEGMENTED NEUTROPHILS+
56 1.61 2.17 HYPERSEGMENTED POLYMORPHS,MACROCYTES+
57 MICRO,HYPO RBCS
58 1.09 1.91 MACROCYTES+,ANISOPOIKILOCYTOSIS
59 0.98 2.56 ANISOPOIKILOCYTOSIS,PLATELETS DECRESED,HYPERSEGMENTED NEUTROPHILS+
60 microcytic hypochromic rbcs,platelets decreased,wbc s decreased.
61 MICRO HYPO RBCS TARGET CELLS
62 BLASTS+,TLC DECREASED.PLT DECREASED
63 ANISOPOILILOCYTOSIS
64 MICRO HYPO RBCS,ELLIPTOCYTOSIS.
65 1.59 3.23 MACROCYTES+,ERYTHROBLASTS+,HYPERSEGMENTED POLYMORPHS,ANISOPOIKILOCYTOSIS+.PLATELETS DECREASED,CLUMPS+
S.NO BONE MARROW STUDY DIAGNOSIS
1 HYPERCELLULAR,MEGALOBLASTIC,ERYTHROID HYPERPLASIA+ MEGALOBLASTIC ANEMIA
2 HYPERCELLULAR,MEGALOBLASTIC MEGALOBLASTIC ANEMIA
3 HYPERCELLULAR,NORMAL PRECURSORS HYPERSPLENISM/CLD
4 hypocellular,fibrosis present,decreased myeloid precursors SLE/CTD
5  MYELOID leukemic blasts  present ACUTE MYELOID LEUKEMIA
6 hypocellular marrow,replaced by fat APLASTIC ANEMIA
7 NORMOCEL,MEGAKAR ADEQ HYPERSPLENISM/CLD
8   LYMPHOID  leukemic blasts present ACUTE LYMPHOID LEUKEMIA
9 hypocellular marrow,replaced by fat APLASTIC ANEMIA
10 HYPERCELLULAR,MEGALOBLASTIC,LARGE MEGAKARYOCYTES+ MEGALOBLASTIC ANEMIA
11 leukemic blasts present ACUTE MYELOID LEUKEMIA
12 normocellular,precursors normal VIRAL INFECTION INDUCED
13 hypocellular,occ megakaryocyte with bare nuclei,dyserythropoiesis,mod decrease in erythroid and myeloid progenitorsHIV INDUCED PANCYTOPENIA
14 HYPERCELLULAR,MEGALOBLASTIC,ERYTHROID HYPERPLASIA+ MEGALOBLASTIC ANEMIA
15 hypocellular marrow,replaced by fat APLASTIC ANEMIA
16 HYPERCELLULAR,NORMAL PRECURSORS HYPERSPLENISM/CLD
17 HYPERCELLULAR,LARGE MEGAKARYOCYTES PRESENT HYPERLOBULATED MEGALOBLASTIC ANEMIA
18 immature myeloid blasts present ACUTE MYELOID LEUKEMIA
19 hypercellular marrow,fragmented erythroblasts+ MYELODYSPLASTIC SYNDROME
20 hypocellular marrow,replaced by fat APLASTIC ANEMIA
21 normocellular,precursors normal VIRAL INFECTION INDUCED
22 HYPERCELLULAR,MEGALOBLASTIC,FEW GIANT METAMYELOCYTE SEEN MEGALOBLASTIC ANEMIA
23 hypocellular marrow,replaced by fat APLASTIC ANEMIA
24 HYPERCELLULAR,MEGALOBLASTIC MEGALOBLASTIC ANEMIA
25 HYPERCELLULAR,MEGALOBLASTIC MEGALOBLASTIC ANEMIA
26 hypercellular marrow, normal precursors HYPERSPLENISM/EHPO
27 HYPERCELLULAR,MEGALOBLASTIC MEGALOBLASTIC ANEMIA
28 hypocellular marrow,replaced by fat APLASTIC ANEMIA
29 hypercellular marrow,ringed sideroblasts+,DYSPLASTIC MYELODYSPLASTIC SYNDROME
30 HYPERCELLULAR,MEGALOBLASTIC,ERYTHROID HYPERPLASIA+ MEGALOBLASTIC ANEMIA
31 immature myeloid blasts present ACUTE MYELOID LEUKEMIA
32 HYPERCELLULAR,MEGALOBLASTIC MEGALOBLASTIC ANEMIA
33 hypocellular marrow,replaced by fat APLASTIC ANEMIA
S.NO. BONE MARROW STUDY DIAGNOSIS
34 HYPERCELLULAR,MEGALOBLASTIC,ERYTHROID HYPERPLASIA+,LARGE MEGAKARYOCYTES PRESENT MEGALOBLASTIC ANEMIA
35 HYPERCELLULAR,MEGALOBLASTIC MEGALOBLASTIC ANEMIA
36 BONE MARROW STUDY DIAGNOSIS
37 hypocellular marrow. SLE/CTD
38 ADEQUATE CELLULARITY WITH MILD TO MODERATE MEGALOBLASTIC CHANGES. HYPERSPLENISM/CLD
39 hypocellular marrow,replaced by fat APLASTIC ANEMIA
40 hypocellular marrow,replaced by fat APLASTIC ANEMIA
41 HYPERCELLULAR,MEGALOBLASTIC MEGALOBLASTIC ANEMIA
42 HYPERCELLULAR,MEGALOBLASTIC MEGALOBLASTIC ANEMIA
43 hypocellular marrow,replaced by fat APLASTIC ANEMIA
44 HYPERCELLULAR,MEGALOBLASTIC,ERYTHROID HYPERPLASIA MEGALOBLASTIC ANEMIA
45 HYPERCELLULAR,MEGALOBLASTIC MEGALOBLASTIC ANEMIA
46 hypocellular marrow,replaced by fat APLASTIC ANEMIA
47 HYPERCELLULAR,MEGALOBLASTIC CHANGES PRESENT MEGALOBLASTIC ANEMIA
48 HYPERCELLULAR,MEGALOBLASTIC,LARGE MEGAKARYOCYTES+ MEGALOBLASTIC ANEMIA
49 HYPERCELLULAR,MEGALOBLASTIC MEGALOBLASTIC ANEMIA
50 hypercellular marrow normal precursors. HYPERSPLENISM/EHPO
51 hypocellular marrow,replaced by fat APLASTIC ANEMIA
52 hypercellular,dyserythropoietic,abnormal megakaryocytes,BINUCLEATED ERYTHROID PRECURSORS MYELODYSPLASTIC SYNDROME
53 hypercellular marrow normal precursors. HYPERSPLENISM/CLD
54 hypocellular marrow,replaced by fat APLASTIC ANEMIA
55 HYPERCELLULAR,MEGALOBLASTIC MEGALOBLASTIC ANEMIA
56 HYPERCELLULAR,MEGALOBLASTIC,LARGE MEGAKARYOCYTES+ MEGALOBLASTIC ANEMIA
57 HYPERCELLULAR,MEGALOBLASTIC,ERYTHROID HYPERPLASIA APLASTIC ANEMIA
58 HYPERCELLULAR,MEGALOBLASTIC MEGALOBLASTIC ANEMIA
59 HYPERCELLULAR,MEGALOBLASTIC MEGALOBLASTIC ANEMIA
60 hypocellular marrow,replaced by fat APLASTIC ANEMIA
61 hypercellular,dyserythropoietic,abnormal megakaryocytes,RINGED SIDEROBLASTS PRESENT MYELODYSPLASTIC SYNDROME
62 lymphoid blasts present. ACUTE LYMPHOID LEUKEMIA
63 hypocellular marrow,replaced by fat APLASTIC ANEMIA
64 hypercellular marrow normal precursors. HYPERSPLENISM/CLD
65 HYPERCELLULAR,MEGALOBLASTIC MEGALOBLASTIC ANEMIA

